CLINICAL STUDY PROTOCOL: INDV-2000-105 
Protocol Title: A Phase I, Open Label Study to Assess the 
Absorption, Metabolism, Excretion, and Mass Balance of a 
Single dose of Oral [14C]-IDV184001AN in Healthy Adult 
Male Participants  
Protocol Number: INDV-2000-105 
Original Protocol Date: 15 May 2023
NCT:
 [STUDY_ID_REMOVED] 
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 1 of 78  
 Clinical Study P rotocol  
 
PROTOCOL TITLE:  
A Phase I , Open Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance 
of a Single dose of Oral [14C]-IDV184001AN  in Healthy Adult Male Participants 
Protocol Number:  INDV- 2000 -105 
Product: IDV184001AN + [14C]-IDV184001AN  
Program Name:  INDV- 2000  
Short  Title:  
Absorption, m etabolism, excretion, and m ass balance study of [14C]-IDV184001 in healthy 
adults  
Study Phase:  Phase I  
Acronym: ADME Study  
Sponsor Name:  Indivior Inc.  
Legal Registered Address:  
Indivior Inc.  
10710 Midlothian Turnpike, Suite 125  
North Chesterfield, VA 23235 USA  
 Regulatory Agency Identifier Number(s)  
Registry  Identifying Number  
IND 145881  
 Approval  Date:   15 May 2023  
 
 
 
 
    
 

INDV -2000  
Clinical Study Protocol: INDV -2000 -105 Final  Indivior  
15 May 2023  
 
Confidential  Page 2 of 80 
 Sponsor Signatories:  

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 3 of 78  MEDICAL MONITOR NAME AND CONTACT INFORMATION 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 4 of 78  CONFIDENTIALITY AND INVESTIGATOR STATEMENT  
Protocol Number: INDV -2000- 105 
Protocol Title: A Phase I , Open Label Study to Assess the Absorption, Metabolism, Excretion, 
and Mass Balance of a Single dose of Oral [14C]-IDV184001AN  in Healthy Adult Male 
Participants   
The information contained in this protocol and all other information relevant to this study drug 
is the confidential and proprietary information of Indivior, and except as may be required by local laws or regulation, may not be disclosed to others without prior written permission of 
Indivior.  
I have read the protocol, including all appendices, and I agree that it contains all of the 
necessary information for me and my staff to conduct this study as described. My staff and/or I will conduct this study as outlined herein, in accordance with the regulations stated in the International Council on Harmonisation E6 / Good Clinical Practice (ICH/GCP) guidelines  and will 
make a reasonable effort to complete the study within the time designated.  
I agree to ensure a ll associates, colleagues , and employees delegated to assist with the conduct 
of the study are trained on this study protocol and amendments, and other study -related 
materials , and are qualified to perform their delegated tasks. I will provide all study pe rsonnel 
copies of the protocol and any amendments , and grant access to all information provided by 
Indivior or specified designees. I will discuss the material with them to ensure that they are fully 
informed about IDV184001AN and appropriate information throughout the study. Mechanisms 
are in place to ensure that site staff receives the appropriate information throughout the study.  
 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 5 of 78  TABLE OF CONTENTS  
 
MEDICAL MONITOR NAME AND CONTACT INFORMATION  ........................................................... 3  
CONFIDENTIALITY AND INVESTIGATOR STATEMENT ..................................................................... 4  
TABLE OF CONTENTS ....................................................................................................................... 5  
TABLE OF TABLES  ............................................................................................................................ 8  
TABLE OF FIGURES .......................................................................................................................... 8  
ABBREVIATIONS  .............................................................................................................................. 9  
1 PROTOCOL SUMMARY ............................................................................................................ 11 
1.1 Synopsis ............................................................................................................................. 11 
1.2 Schema  .............................................................................................................................. 15  
1.3 Schedule of Events (SoE)  ................................................................................................... 16 
2 INTRODUCTION  ....................................................................................................................... 19 
2.1 Study Rati onale  ................................................................................................................. 19 
2.2 Background ....................................................................................................................... 20 
2.2.1  INDV- 2000 (IDV184001)  .......................................................................................... 20 
2.3 Benefit/Risk Assessment  ................................................................................................... 22 
2.3.1  Risk Assessment  ...................................................................................................... 22 
2.3.2  Benefit Assessment  ................................................................................................. 22 
2.3.3  Overall Benefit -risk Conclusion  ............................................................................... 23 
3 OBJECTIVES AND ENDPOINTS  ................................................................................................. 24 
4 STUDY DESIGN  ........................................................................................................................ 26 
4.1 Overall Design  ................................................................................................................... 26 
4.1.1  Discharge  Criteria  .................................................................................................... 27 
4.2 Scientific Rationale for Study Design ................................................................................ 27 
4.3 Justification for Dose  ........................................................................................................ 28 
4.4 End of Study Definition ..................................................................................................... 28 
4.5 Protocol Deviations  ........................................................................................................... 29 
5 STUDY POPULATION  ............................................................................................................... 30 
5.1 Inclusion Criteria  ............................................................................................................... 30 
5.2 Exclusion Criteria ............................................................................................................... 30 
5.3 Lifestyle Considerations  .................................................................................................... 32 
5.3.1  Meals and Dietary Restrictions  ............................................................................... 32 
5.3.2  Caffeine, Alcohol, and Tobacco  .............................................................................. 32 
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 6 of 78  5.3.3  Activity  .................................................................................................................... 33 
5.4 Screen Failures  .................................................................................................................. 33 
5.5 Enrolled Participant  .......................................................................................................... 33 
5.6 Early Discontinuation  ........................................................................................................ 33 
6 STUDY DRUG AND CONCOMITANT THERAPY ......................................................................... 34 
6.1 Study Drug(s) Administered  .............................................................................................. 34 
6.2 Preparation, Handling, Storage, and Accountability  ........................................................ 35 
6.2.1  Drug Administration  ................................................................................................ 35 
6.2.2  Reporting Product Complaints  ................................................................................ 36 
6.3 Assignment to Study Intervention .................................................................................... 36 
6.4 Blinding/Masking .............................................................................................................. 36 
6.5 Study Drug Compliance  ..................................................................................................... 37 
6.6 Dose Modification ............................................................................................................. 37 
6.7 Treatment Access to Study Drug After the End of the Study  ........................................... 37 
6.8 Treatment of Study Drug Overdose  .................................................................................. 37 
6.9 Prior and Concomitant Therapy  ........................................................................................ 37 
7 DISCONTINUATION/WITHDRAWAL AND STOPPING CRITERIA  ............................................... 39 
7.1 Discontinuation from Study and Study Stopping Criteria  ................................................. 39 
7.2 Participant  Discontinuation/Withdrawal From the Study  ................................................ 39 
7.3 Lost to Follow -up .............................................................................................................. 39 
8 STUD Y ASSESSMENTS AND PROCEDURES  .............................................................................. 41 
8.1 Administrative  Procedures  ............................................................................................... 42 
8.1.1  Informed Consent Procedure  ................................................................................. 42 
8.1.2  Inclusion and Exclusion Criteria  .............................................................................. 42 
8.1.3  Medical History/Demography ................................................................................. 42 
8.1.4  Concomitant Medications  ....................................................................................... 42 
8.1.5  Check -in Criteria  ...................................................................................................... 42 
8.2 Efficacy and/or Immunogenicity Assessments  ................................................................. 42 
8.3 Safety Assessments ........................................................................................................... 42 
8.3.1  Physical Examinations  ............................................................................................. 43 
8.3.2  Vital Signs  ................................................................................................................ 43 
8.3.3  Electrocardiograms  ................................................................................................. 43 
8.3.4  Clinical Safety Laboratory Tests  .............................................................................. 43 
8.3.5   ................................................... 44 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 7 of 78  8.4 Adverse Events, Serious Adverse Events, and Other Safety Reporting  ............................ 45 
8.4.1  Time Period and Frequency for Collecting AE and SAE Information  ...................... 48 
8.4.2  Method of Detecting AEs and SAEs  ........................................................................ 49 
8.4.3  Reporting and Follow- up of AEs and SAEs  .............................................................. 49 
8.4.4  Regulatory Reporting Requirements for SAEs  ........................................................ 50 
8.4.5  Pregnancy ................................................................................................................ 50 
8.5 Pharmacokinetics  .............................................................................................................. 51 
8.6 Pharmacodynamics  ........................................................................................................... 52 
8.7 Gene tics ............................................................................................................................ 52 
8.8 Biomarkers  ........................................................................................................................ 52 
8.9 Medical Resource Utilisation and Health Economics  ....................................................... 52 
9 STATISTICAL CONSIDERATIONS  .............................................................................................. 53 
9.1 Statistical Hypotheses  ....................................................................................................... 53 
9.1.1  Multiplicity Adjustment  .......................................................................................... 53 
9.2 Analyses  Sets ..................................................................................................................... 53 
9.3 Statistical Analyses  ............................................................................................................ 53 
9.3.1  General Considerations ........................................................................................... 53 
9.3.2  Primary Endpoints Analysis  ..................................................................................... 53 
9.3.3  Secondary Endpoints Analysis  ................................................................................ 54 
9.3.4  Tertiary Endpoints Analysis  ..................................................................................... 54 
9.4 Interim Analysis  ................................................................................................................. 54 
9.5 Sample  Size Determination  ............................................................................................... 55 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ............................. 56 
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Consider ations ...................... 56 
10.1.1  Regulatory and Ethical Considerations  ................................................................... 56 
10.1.2  Financial Disclosure  ................................................................................................. 56 
10.1.3  Informed Consent Process  ...................................................................................... 57 
10.1.4  Data Protection  ....................................................................................................... 57 
10.1.5  Dissemination of Clinical Study Data  ...................................................................... 57 
10.1.6  Data Quality Assurance  ........................................................................................... 58 
10.1.7  Source Documents  .................................................................................................. 59 
10.1.8  Study and Site Start and Closure  ............................................................................ 59 
10.1.9  Publication Policy  .................................................................................................... 60 
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 8 of 78  10.2  Appendix 2: Clinical Laboratory Tests  ........................................................................ 60 
10.3  Appendix 3: Contraceptive Guidance and Collection of Pregnancy Information ...... 62 
10.3.1  Contraception Guidance  ......................................................................................... 62 
10.4  Appendix 4: Pharmacokinetic Sampling Schedule  ..................................................... 63 
10.5  Appendix 5:Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive  Vaccine Clinical Trials  ......................................................................... 68 
I. Introduction ............................................................................................................ 69 
II. Background ............................................................................................................. 70 
III. Toxicity grading scale  tables ................................................................................... 70 
IV. References  .............................................................................................................. 76 
10.6  REFERENCES  ................................................................................................................ 77 
 
TABLE OF TABLES  
Table 1  Objectives and Endpoints  ........................................................................................... 12 
Table 2  Study Drug Administered  ........................................................................................... 34 
Table 3  Blood Volume during the Study  ................................................................................. 41 
Table 4  Populations for Analysis  ............................................................................................. 53 
Table 5  Protocol -required Safety Laborat ory Tests  ................................................................ 61 
Table 6  Blood PK sampling schedule  ....................................................................................... 63 
Table 7  Urine sampling schedule  ............................................................................................ 64 
Table 8  Fecal sampling schedule  ............................................................................................. 65 
Table 9  List of Whole Blood and Plasma Pharmacokinetic Parameters (non -exhaustive) ..... 66 
Table 10  List of Urine and Feces Pharmacokinetic Parameters (non -exhaustive) ................... 67 
 
TABLE OF FIGURES  
Figure 1  Study Schema  ............................................................................................................. 15 
Figure 2  Schedule of Events (SoE)  ............................................................................................ 16 
 
  
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 9 of 78  ABBREVIATIONS  
ADME a bsorption, distribution, metabolism, and elimination  
AE adverse event  
AIDS  acquired immunodeficiency syndrome  
ALP alkaline phosphatase  
ALT aspartate aminotransferase  
AST alanine aminotransferase  
  
CFR Code of Federal Regulations  
CNS central nervous system  
COVID -19 coronavirus disease 2019  
CRF Case Report Form 
CYP cytochrome P450  
DORA  dual orexin receptor antagonist  
ECG electrocardiogram 
EOS end of study  
FDA Food and Drug Administration 
GCP Good Clinical Practice  
HBsAg  hepatitis B surface antigen 
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICF Informed  Consent Form  
ICH International Council on Harmonisation  
IEC Independent Ethics Committee  
IND investigational new drug  
INR international normalised ratio  
IRB Institutional Review Board 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 10 of 78 LSC liquid scintillation counting  
M12  INDV- 2000 demethylated metabolite 
OUD  opioid use disorder  
OX1R/OX2R  orexin -1/orexin -2 receptor  
PK pharmacokinetic (s) 
QTcF  heart rate -corrected QT interval  
SAE serious adverse event  
SAP statistical analysis plan  
SoE Schedule of Events  
SOP Standard operating procedure  
SUSAR  suspected unexpected serious adverse reaction  
TEAE  treatment emergent adverse event  
TRA total radioactivity  
ULN  upper limit of normal 
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 11 of 78 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol Title:  
A Phase I , Open Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance 
of a Single dose of Oral [14C]-IDV184001AN  in Healthy Adult Male Participants 
Short Title:  
Absorption, m etabolism, excretion, and m ass balance study of [14C]-IDV184001 in healthy 
adults  
Regulato ry Agency Identifier Number(s):  
Registry  Identifying  Number  
IND 145881  
Rationale:  
The disposition of any drug in the body is controlled by physiological processes affecting 
absorption, metabolism, and excretion. The most efficient and well -established approach to 
elucidate these processes is a mass balance study in which the drug dose is administered in 
radiolabelled form, followed by collection and analysis of different biological matrices. 
Radioactivity will be quantitated using liquid scintillation counting  (LSC) and determination of 
drug and metabolite concentrations using conventional liquid chromatography -tandem mass 
spectrometry.  
The purpose of this open label study is to characteri se the abs orption, metabolism, excretion, 
and mass balance of [14C]-IDV184001 *, in healthy adult male participants. 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 12 of 78 * Note: IDV184001 is the active moiety of IDV184001AN.  
Objectives and Endpoints  
Table 1 Objectives and Endpoints  
Objectives Endpoints 
Primary   
• To investigate the route(s) of elimination 
and the overall mass balance of IDV184001, 
following a single oral dose of [
14C]-IDV184001AN  in healthy adult male 
participants . • Total radioactivity  (TRA) recovery and the 
percent of the radioactive dose excreted in the urine and feces  [Time Frame: Pre -dose to 168 
hours post- dose , collection time can be 
extended] . 
• To quantitate TRA in whole blood, plasma, 
urine, and feces following a single oral dose of [
14C]-IDV184001AN  in healthy adult male 
participants. • TRA PK parameters in plasma  and whole blood : 
AUC last, AUC 0-∞, AUC extrap(%) , Cmax, Tmax, λz, and 
T1/2 as data permits  [Time Frame: Pre -dose to 
168 hours post -dose , collection time can be 
extended] . 
• TRA PK parameters  in urine and feces: Ae t1-t2, 
CumAe, %Dose, Cum%Dose, and CL r (urine only)  
[Time Frame: Pre -dose to 168 hours post -dose , 
collection time ca n be extended] . 
• To characteri se the PK profile of unlabel led 
IDV184001 and M12 in plasma following a 
single oral dose of [14C]-IDV184001AN  in 
healthy adult male participants. • Unlabel led IDV184001  and M12 PK parameters 
in plasma: AUC last, AUC 0-∞, AUC extrap(%) , Cmax, Tmax, 
λz, T1/2, as data permits  [Time Frame: Pre -dose 
to 168 hours post -dose ]. 
• Ratio of unlabelled IDV184001 and M12 in 
plasma to plasma TRA for AUC last and C max, 
where appropriate  [Time Frame: Pre -dose to 
168 hours post -dose ]. 
• To characteri se metabolite identification , 
profiling and quantitation for IDV184001 in 
plasma, urine, and feces  following a single 
oral dose of [14C]-IDV184001AN  in healthy 
adult male participants . • IDV184001  metabolite identification , profiling 
and quantitation in plasma, urine, and fecal 
samples  [Time Frame: Pre -dose to 168 hours 
post -dose , collection time can be extended] . 
• To determine the ratio of TRA 
concentration equivalents in whole blood • The ratio of TRA concentration equivalents  in 
whole blood relative to plasma at each 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 13 of 78 versus plasma following a single oral dose 
of [14C]-IDV184001AN  in healthy adult male 
participants. time -matched determination of TRA in whole 
blood and plasma  [Time Frame: Pre -dose to 
168 hours post -dose , collection time can be 
extended] . 
 
Secondary   
• To assess the safety and tolerability of a 
single oral dose of [14C]-IDV184001AN  as 
determined by AE reporting . • Incidence, seriousness, severity, and relatedness 
of treatment emergent adverse event s (TEAEs ). 
Tertiary/Exploratory  
Overall Design  Synop sis: 
This is an open -label,  single -dose study in healthy adult male participants.  
Brief Summary:  
The purpose of this study is to characteris e the absorption, metabolism, and excretion, and 
mass balance  of [14C]-IDV184001. 
Participants who meet the eligibility criteria will be admitted to the study site on Day -1 and will 
remain confined until at least Day 8 (if at least one discharge criterion is  met) or up to a 
maximum stay of 21  days post -dose  (ie, Day 2 2). 
On Day 1, participant s will receive a single oral dose of 200 mg (~100 µCi ) [14C]-IDV184001AN . 
Blood ( for plasma and whole blood), urine , and fecal samples will be collected pre -dose and for 
at least 168  hours post- dose  (ie, Day 8) to measure TRA (all sample matrices),  and for 
metabolite identification, profiling and quantitation (plasma, urine , and feces), as appropriate. 
Blood samples for plasma concentrations of unlabelled IDV184001 and M12 will also be 
collected pre-dose and for 168  hours post- dose.  
Participants  may be discharged from the study site following the 168 -hour post -dose blood 
draw  and/or study procedures on Day 8, if at least one discharge criterion is met (refer to 
Section  4.1.1). If neither discharge criteria is met by 168  hours post -dose (ie,  Day 8), 
participant s will remain confined at the study site until at least one discharge criterion is met or 
a maximum stay of 21 days post -dose is reached (ie,  Day 22), whichever is first. For participants 
who remain confined past Day  8, collection of urine and fecal samples for TRA determination 
and metabolite identification, profiling and quantitation will continue in 24 -hour intervals and 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 14 of 78 collection of blood for TRA determination ( whole blood and plasma) and metabolite 
identification, profiling and quantitation ( plasma) will continue in 72- hour inte rvals.  
Participants who terminate the study early will be asked to return to the study site 7±2 days 
after dosing for follow -up procedures, and to determi ne if any AE has occurred since the last 
study visit.  
Number of Participants:  
Approximately 7 participants will be enrolled to ensure 6 participants complete the study. The 
sample size was selected without statistical considerations. It has been determined adequate to 
meet the study objectives  and is in accordance to the FDA guidance ( FDA 2022) . This sample 
size is limited based on clinical considerations for this type of study and in order to limit exposure to radioactivity.  
Note : A participant will be considered enrolled at the time he receives the study drug . 
Study Treatment and Duration:  
On Day 1, p articipants will receive a single oral dose  of 200 mg (~100 µCi) [
14C]-IDV184001AN . 
The total planned study duration (screening  to EO S) for each participant will be up to 7 weeks. 
This includes a screening period of up to 4  weeks (ie, within 28 days prior to dosing on Day 1) 
and a treatment period of at least 1  week (Days 1 to 8) until at least one discharge criterion is 
met, up to maximum of 3 weeks (Days 1 to 22).  Participant s who terminate the study early will 
be asked to return to the study site 7±2 days after dosing for follow -up procedures, and to 
determine if any AE has occurred since the last study visit.  
Data Monitoring/Other Committee: No 
  
INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 15 of 78 1.2 Schema  
Figure 1 Study Schema  
 
 

INDV- 2000  
Clinical Study Protocol: INDV -2000 -105 Final Indivior  
15 May  2023  
 
Confidential  Page 16 of 78 
 1.3 Schedule of Events (SoE)  
Figure 2 Schedule of Events (SoE)  
Study Procedures 1 Scr 2 Treatment Period (Days)  Discharge /
EOS 4 ET 5 –1 3 1 2 3 4 5 6 7 8 9-22 
Informed consent X             
Inclusion and exclusion criteria  X             
Review Check -In Criteria 6  X            
Demograph ics X             
Medical history  X             
Full physical examination 
including height and weight  7 X X          X  
COVID -19 screen (rapid test)   X            
HIV, Hepatitis B, and C (antibody)  X             
Drug and alcohol screen  X X            
Haematology, serum chemistry 8, 
urinalysis  X X  X   X  X   X X 
Coagulation  X   X     X   X X 
AE review  X X X X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X X X X 
[14C]-IDV184001AN  dosing    X           

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 17 of 78 Study Procedures 1 Scr 2 Treatment Period (Days)  Discharge /
EOS 4 ET 5 –1 3 1 2 3 4 5 6 7 8 9-22 
Blood for unlabel led IDV184001 
and M12 plasma PK    X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12    
Blood for whole blood TRA 13   X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12   
Blood for plasma TRA 13   X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12   
Blood for plasma metabolic 
profiling 13   X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12 X 12   
Urine for TRA and metabolic 
profiling 14   X X X X X X X X X   
Feces for TRA and metabolic 
profiling 15   X X X X X X X X X   
AE=adverse event;  COVID -19=Coronavirus disease 2019 ;  EOS=End of study; ET=early 
termination; HIV=Human immunodeficiency; PK=pharmacokinetic; Scr=Screening ; TRA= Total radioactivity   
1. For details on procedures, refer to Section 8 . 
2. Within 28 days prior to  dosing.  
3. Participants will be admitted to the study site on Day - 1, at the time indicated by the study site, and will remain confined until 
Day 8, if at least one discharge criterion is met. If neither discharge criteria is met by Day 8, participants will remain confined at 
the study site until at least one discharge criterion is met or a maximum stay of 21  days post -dose is reached (ie,  Day 22), 
whichever is first.  
4. To be conducted prior to the discharge from study unit. Participant will be  discharge d from the study unit as of Day  8, after at 
least one discharge criterion is met or after the maximum stay of 21 days post -dose, on Day 22. Since an approximate 24 -hour 
time lag is anticipated for TRA measurement, actual participant  release from the study site may occur 1  day after a discharge 
criterion is met.  
5. Participant  who terminate the study early will be asked to return to the study site 7±2 days after dosing for follow -up 
procedures, and to determine if any AE has occurred since the last study visit.  
6. For details on Check -In Criteria, see Section 8.1.5. 
7. Heig ht collected at screening only.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 18 of 78 8. Samples for serum chemistry will be obtained after a fast of at least 12 hours, however, in case of dropouts or rechecks, 
participants may not have fasted for 12 hours prior to when the serum chemistry sample is taken.  
9. To be collected within 2 hours prior to dosing  (pre- dose) and at 1 hour (±20  minutes ), 2 hours (± 20 minutes ), and 4 hours 
(±20 minutes ) post -dose . 
10. To be collected within 2 hours prior to dosing (pre -dose) and at 1 hour (±15  minutes ), 2 hours (± 15 minutes ), and 4 hours 
(±15 minutes ) post -dose. 
12. For blood sample collection time po ints, please refer to Section 10.4  (Appendix 4 ). 
13. Blood samples will be samples will be collected for at least 168  hours post -dose , at the time points indicated. If neither discharge 
criteria (see Section  4.1.1) is  met by 168 hours post -dose (ie, Day 8), sampling for TRA determination (plasma and whole blood) 
and metabolite identification, profiling and quantitation (plasma) will continue every 72 hours thereafter, until at least one  
discharge criterion is  met or up to a maximum stay of 21 days post -dose (ie, Day 22).  
14. Urine collection for analysis of TRA and metabolite identification, profiling and quantitation will be conducted at the following 
intervals: pre -dose  (spot collection), 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours post- dose, and in  24-hour  intervals  until at least 
168 hours post -dose (ie, Day 8). If neither discharge criteria (see Section  4.1.1) is met by 168  hours post dose (ie, Day 8), urine 
collection will continue in 24 -hour intervals thereafter, until at least one discharge criterion is met or up to a maximum stay of 
21 days post -dose (ie,  Day 22). 
15. Fecal collection for the analysis of TRA and metabolite identification, profiling and quantitation will be conducted pre -dose  
(within 48 hours pre -dose)  and in 24 -hour intervals for at least 168  hours post- dose (ie,  Day 8). If neither discharge criteria (see 
Section 4.1.1) is met by 168  hours post -dose (ie, Day 8), fecal collection will continue in 24 -hour intervals thereafter, until at least 
one discharge criterion is met or up to a maximum stay of 21  days post -dose (ie, Day  22). 
 

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 19 of 78 2 INTRODUCTION  
INDV- 2000 (also referred to as C4X_3256) is a highly potent and selective OX1R antagonist that 
is being developed as a therapy for the treatment of OUD.  
2.1 Study Rationale  
The disposition of any drug in the body is controlled by physiological processes affecting 
absorption, metabolism, and excretion. The most efficient and well -established approach to 
elucidate these processes is a mass balance study in which the drug dose is administered in 
radiolabell ed form, followed by collection and analysis of different biological matrices. 
Radioactivity will be quantitated using  LSC and determination of drug and metabolite 
concentrations using conventional liquid chromatography -tandem mass spectrometry . 
The purpose of this open label study is to characterise the absorption, metabolism, excretion, 
and mass balance of [14C]-IDV184001 * in healthy adult male participants.  
* Note: IDV184001 is the active moiety of IDV184001AN.  
 

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 20 of 78 2.2 Background 
2.2.1 INDV -2000 (IDV184001)  
INDV- 2000 is a potent and competitive antagonist of the human OX1R with good selectivity in 
vitro. In humans, the OX1R is expressed in the brain, predominantly in projections from the 
lateral hypothalamus, including the ventral tegmental area and the ventromedial prefrontal 
cortex and it binds the neuropeptide Orexin- A and, with less affinity, Orexin -B. The number of 
Orexin -A producing neurons is increased in the brains of individuals with heroin dependence 
(Thannickal 2018). Antagonism of the OX1R inhibits addiction- related behaviours in non- clinical 
rodent models including self- administration, relapse to drug seeking, and withdrawal 
(Azizi 2010, Mahler 2012, Hooshmand 2017, Dunn 2019 ). Hence it is hypothesised that OX1R 
antagonists should show clinical benefit in the treatment of substance use disorders, including 
OUD, by reducing craving, relapse, and symptoms of withdrawal.  
There are several selective OX1R antagonists (eg, ACT -539313, JNJ -61393215, AZD4041, 
CVN766) and dual OX1R/OX2R antagonists already in clinical development. BELSOMRA® (suvorexant), DAYVIGO® (lemborexant) and Q UVIVIQ ® (daridorexant) are dual OX1R/OX2R 
antagonists approved for the treatment of insomnia ( Coleman 2017, Murphy 2017 , Markham 
2022) . There have been no published reports of any significant safety issues in animals or 
humans with these compounds.  
The most relevant data on INDV -2000 for the present study are summarised below. A detailed 
description of the chemistry, pharmacology, efficacy, and safety of INDV- 2000 is provid ed in the 
most recent IB.  
Nonclinical summary  
INDV- 2000 underwent a comprehensive program of non -clinical pharmacology, PK, and 
toxicology investigations.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 21 of 78 Clinical summary  
Additional in
formation on PK  and safety of INDV -2000 is provided in the most recent IB.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 22 of 78 2.3 Benefit/Risk Assessment  
Benefit and risk assessment are highlighted below; however more detailed information about 
the known and expected benefits and risks and re asonably expected AEs of  INDV- 2000 are 
found in the  IB. 
2.3.1 Risk Assessment  
Investigational Study Drug :  
Study Proce
dures : 
A potential risk associated with study procedures are the risks associated with phlebotomy since multiple blood samples are collected throughout the study period. However, limits for number of samples and sample volumes are in place, according to local guidance.  
2.3.2 Benefit Assessment  
Participants in this clinical study will not receive direct health benefits from study drug during participation. An indirect health benefit to the participants enrolled in this study is the free 
medical tests received at screening and during the study.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 23 of 78 2.3.3 Overall Benefit -risk Conclusion  
This is a study in healthy participants, and there is no direct benefit to study participants. The 
data obtained from this healthy participant study may inform future  clinical studies in 
participants with OUD or other indications under study.  
Administration of a single oral dose of 200 mg (~100 µCi ) [14C]-IDV184001AN  is not expected to 
cause any safety co ncern in healthy male participants.  The estimated total radioactive dose and 
the tissue specific exposure from a single oral administration of ~ 100 µCi of [14C]-IDV184001AN  
are below the radiation d ose limits set forth by the FDA ( FDA 2023). Thus, the health risk 
resulting from exposure to radiation in the study drug is very low.  
The study site will follow a risk management plan to minimise the exposure of participants to COVID -19. The IRB / IEC approved COVID -19 clinical pharmacology unit management plan will 
be provided separately.  
The safety monitoring practices employed by this protocol  
 are adequate to protect 
the participants’ safety and should detect al l expected TEAEs.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 24 of 78 3 OBJECTIVES  AND  ENDPOINTS 
Objectives Endpoints 
Primary   
• To investigate the route(s) of elimination 
and the overall mass balance of IDV184001, 
following a single oral dose of [
14C]-IDV184001AN  in healthy adult male 
participants . • TRA recovery and the percent of the 
radioactive dose excreted in the urine and feces  [Time Frame: Pre -dose to 168 hours 
post -dose , collection time can be 
extended] . 
• To quantitate TRA in whole blood, plasma, 
urine, and feces following a single oral dose 
of [14C]-IDV184001AN  in healthy adult male 
participants. • TRA PK parameters in plasma  and whole 
blood : AUC last, AUC 0-∞, AUC extrap(%) , Cmax, 
Tmax, λz, and T 1/2 as data permits  [Time 
Frame: Pre -dose to 168 hours post- dose , 
collection time can be extended].  
• TRA PK parameters  in urine and feces : 
Aet1-t2, CumAe, %Dose, Cum%Dose, and 
CLr (urine only)  [Time Frame: Pre -dose to 
168 hours post -dose , collection time can 
be extended] . 
• To characteri se the PK profile of unlabel led 
IDV184001 and M12 in plasma following a 
single oral dose of [14C]-IDV184001AN  in 
healthy adult male participants. • Unlabel led IDV184001  and M12 PK 
parameters in plasma: AUC last, AUC 0-∞, 
AUC extrap(%) , Cmax, Tmax, λz, T1/2, as data 
permits  [Time Frame: Pre -dose to 168 
hours post- dose ]. 
• Ratio of unlabelled IDV184001 and M12 
in plasma to plasma TRA for AUC last and 
Cmax, where appropriate  [Time Frame: 
Pre-dose to 168  hours post -dose ]. 
• To characteri se metabolite identification, 
profiling and quantitation for  IDV184001 in 
plasma, urine, and feces  following a single 
oral dose of [14C]-IDV184001AN  in healthy 
adult male participants . • IDV184001  metabolite identification, 
profiling  and quantitation in plasma, 
urine, and fecal samples  [Time Frame: 
Pre-dose to 168 hours post -dose , 
collection time can be extended] . 
• To determine the ratio of TRA 
concentration equivalents in whole blood 
versus plasma following a single oral dose of [
14C]-IDV184001AN  in healthy adult male 
participants. • The ratio of TRA concentration 
equivalents in whole blood relative to plasma at each time -matched 
determination of TRA in whole blood 
and plasma [Time Frame: Pre -dose to 
168 hours post -dose , collection time can 
be extended] . 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 25 of 78 Secondary   
• To assess the safety and tolerability of a 
single oral dose of [14C]-IDV184001AN  as 
determined by AE reporting . • Incidence, seriousness, severity, and 
relatedness of TEAEs . 
Tertiary/Exploratory  

I N D V- 2 0 0 0  
Cli nic al St u dy Pr ot oc ol: I N D V -2 0 0 0 -1 0 5 Fi n al  I n di vi or  
1 5  M a y 2 0 2 3  
 
C o nfi d e nti al  P a g e 2 6  of 7 8  4 S T U D Y D E SI G N  
4. 1  O v er all D esi g n  
 T his is a n o p e n l a b el, si n gl e -d os e  st u d y i n h e alt hy a d ult p artici p a nts.  
 A p pr oxi m at el y 7 m al e p artici p a nts will b e e nr oll e d t o pr ovi d e at l e ast 6 c o m pl et e d  
p artici p a nts. 
 T h e t ot al pl a n n e d st u d y d ur ati o n (scr e e ni n g t o E O S) f or e ac h p artici p a nt will b e  u p t o  
7 w e e ks. T his i ncl u d es a scr e e ni n g p eri o d  a n d a tr e at m e nt  p eri o d : 
o Scr e e ni n g: D a y -2 8 u p t o d osi n g o n D a y 1 ; 
o Tr e at m e nt P eri o d: D a y 1 t o  u p t o m axi m u m  D a y 2 2  
 D a y - 1: C h ec k -i n at t h e ti m e i n dic at e d b y t h e st u d y sit e, f or eli gi bl e 
p artici p a nts. 
 D a y 1: P artici p a nts will r ec ei v e a si n gl e or al d os e of 2 0 0 m g ( ~ 1 0 0 µ Ci ) 
[1 4 C]- I D V 1 8 4 0 0 1 A N . 
 D a ys 2 t o 7: All p artici p a nts will r e m ai n i n t h e st u d y sit e . 
 D a y 8- 2 2 : P artici p a nts w h o m e et at l e ast o n e disc h ar g e crit eri o n  will b e 
r el e as e d fr o m t h e st u d y sit e  st arti n g o n D a y 8 (r ef er t o S ecti o n  4. 1. 1 ). If 
n eit h er disc h ar g e crit eri o n is m et b y D a y 8, p artici p a nt will r e m ai n c o nfi n e d 
u ntil at l e ast o n e disc h ar g e crit eri o n is m et or u p t o a m axi m u m st a y of 2 1 
d a ys p ost -d os e (i e,  D a y 2 2) , w hic h e v er is first . 
 Disc h ar g e / E O S : C h ec k -o ut fr o m t h e st u d y sit e f oll o wi n g c o m pl eti o n of t h e 
pr oc e d ur es sc h e d ul e d at disc h ar g e ; n ot e t h at a n a p pr oxi m at e 2 4 -h o ur ti m e 
l a g is a ntici p at e d f or T R A m e as ur e m e nt, act u al p artici p a nt r el e as e fr o m t h e 
st u d y sit e m a y occ ur 1  d a y aft er a disc h ar g e crit eri o n is m et.  
 P artici p a nts w h o t er mi n at e t h e st u d y e arly will b e as k e d t o r et ur n t o t h e st u d y 
sit e 7 ± 2 d a ys aft er d osi n g f or f oll o w - u p pr oc e d ur es, a n d t o d et er mi n e if a n y 
A E h as occ urr e d si nc e t h e l ast st u d y visit.  
 Bl o o d s a m pli n g f or u nl a b ell e d I D V 1 8 4 0 0 1  a n d M 1 2 pl as m a c o nc e ntr ati o ns will b e 
c o n d uct e d pri or t o d osi n g o n D a y 1 a n d f or 1 6 8  h o urs p ost -d os e.  
 Bl o o d s a m pli n g  f or w h ol e bl o o d T R A will b e c o n d uct e d f or at l e ast  1 6 8  h o urs p ost -d os e.  If 
n eit h er disc h ar g e crit eri a (s e e S ecti o n  4. 1. 1 ) is m et b y 1 6 8  h o urs p ost -d os e (i e, D ay 8), 
s a m pli n g f or w h ol e bl o o d T R A d et er mi n ati o n will c o nti n u e ev er y 7 2  h o urs t h er e aft er, u ntil 
at l e ast o n e disc h ar g e crit eri o n is m et or u p t o a m axi m u m st a y of 2 1 d a ys p ost -d os e (i e, 
D a y 2 2).  
 Bl o o d s a m pli n g f or pl as m a T R A pl as m a a n d m et a b olit e i d e ntific ati o n, pr ofili n g a n d 
q u a ntit ati o n will b e c o n d uct e d f or at l e ast 1 6 8 h o urs p ost -d os e. If n eit h er disc h ar g e crit eri a 
(s e e S ecti o n  4. 1. 1 ) is m et b y 1 6 8  h o urs  p ost -d os e (i e, D a y 8), s a m pli n g f or pl as m a T R A 
d et er mi n ati o n a n d m et a b olit e i d e ntific ati o n, pr ofili n g a n d q u a ntit ati o n  will c o nti n u e e v ery 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 29 of 78 4.5 Protocol Deviations  
A protocol deviation is any non -compliance with the clinical study protocol or ICH/GCP 
requirements. The non- compliance may be either on the part of the participant, the 
Investigator, or the study -site staff. It is the responsibility of the I nvestigator and study -site staff 
to use continuous vigilance to identify and report deviations to Indivior or specified designee, 
and to the IRB/ IEC per local requirements.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 30 of 78 5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following cr iteria apply:  
1. Participant must be  19 to 55 years of age inclusive, at the time of signing the 
informed consent.  
2. Participant must have body weight of a minimum of 50.0 kg at the S creening Visit 
and body mass index within the range 18.0 to 32.0 kg/m2 (inclus ive).  
3. Participant  must be male and who is healthy  as determined by medical evaluation.  
4. Participant  agree s to follow contraception guidelines in Section  10.3  (Appendix 3 ). 
5. Participant must be continuous non -smoker who has not used nicotine - and 
tobacco- containing products for at least 3  months prior to dosing based on 
participant  self-reporting . 
6. Participant must be capable of giving signed informed consent as described in 
Section  10.1.3 (Appendix 1 ) which includes compliance with the requirements and 
restrictions listed in the ICF  and in this protocol.  
5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Have an ongoing medical history of clinically significant neurological, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, psychiatric or other 
disorder as judged by an I nvestigator that could potentially affect the study 
outcomes or compromise participant safety.  
2. Have clinically significant abnormal biochemistry, haematology or urinalysis results as judged by an Investigator . 
3. Have a history of narcolepsy or sleep apnea . 
4. Have disorders that may interfere with drug absorption, distribution, metabolism and excretion processes . 
5. Current active hepatic or biliary disease .  
6. Participants with cholecystectomy <90 days prior to the S creening Visit . 
7. Positive test results fo r HIV- 1/HIV- 2 antibodies, HBsAg  or Hepatitis C antibodies at 
the Screening Visit . 
8. Have a blood pressure reading outside of the following range: Systolic <86  or 
>149 mmHg; Diastolic <50 or >94 mmHg  at the Screening Visit.  
9. Serious cardiac illness or other medical condition including, but not limited to:  
 Uncontrolled arrhythmias  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 31 of 78  History of congestive heart failure  
 QTcF >450 msec or history of prolonged QT syndr ome   
 Myocardial infarction  
 Uncontrolled symptomatic angina  
10. History of suicidal ideation within 30 days prior to providing written informed 
consent as evidenced by answering "yes' to questions 4 or 5 on the suicidal ideation portion of the C -SSRS completed  at the Screening Visit or history of a suicide 
attempt (per the C -SSRS) in the 6 months prior to informed consent.  
11. Healthy participants  who are taking, or have taken, any prescribed or 
over -the- counter drugs (other than 2 g rams  of acetaminophen per 24-hour period as 
of Day 1  or thyroid hormone replacement  therapy [see Section  6.9]) or herbal 
remedies in the 14 days or 5 half -lives (whichever is  longer) prior to dosing  of study 
drug .  
12. Treatment with any known drugs that are moderate or strong inhibitors/inducers of CYP3A4 or CYP2C19, including St. John’s Wort, within 30 days prior to dosing  of 
study drug.  
13. Any consumption of food or drink containi ng poppy seeds, grapefruit or Seville 
oranges within 14 days prior to dosing of study drug.  
14. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).  
15. Positive test result for alcohol and/or drugs of abuse at the S creening Visit or at 
check -in. 
16. Concurrent treatment or treatment with an investigational drug or device within 30 days or 5 half-lives (whichever is longer) prior to dosing  of study drug.  
17. Blood donation of approximately 500 mL or more within 56 days or plasma donation within 7 days prior to  the S creening  Visit . 
18. Known hypersensitivity to INDV -2000.  
19. Has less than 1  bowel movement every 2  days.  
20. Recent history of abnormal bowel movements, such as diarrhea, loose stools o r 
constipation, within 2 weeks prior to dosing  of study drug . 
21. Has received radiolabell ed substances or has been exposed to radiation sources over 
the past 12 months or is likely to receive radiation exposure or radioisotopes with in 
the next 12  months such  that participation in this study would increase their total 
exposure beyond the recommended levels considered safe (ie, weighted annual limit recommended by the FDA 21CFR361 of 3000  mrem; FDA 2023 ). 
22. Site staff and/or participants who have a financial interest in, or an immediate family 
member of either the site staff and/or Indivior employees, directly involved in the 
study. 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 32 of 78 23. Major surgical procedure (as defined by the Investigator) within 90 days prior to 
dosing of study drug or still recovering from prior surgery.  
24. Concurrent enrolment in another clinical study, unless it is an observational study.  
25. Participants who are unable, in the opinion of the I nvestigator, to comply fully with 
the study requirements.  
26. Any condition that, in the opinion of the I nvestigator or Indivior, would interfere 
with evaluation of the study drug or interpretation of participant safety or study results.  
5.3 Lifestyle Considerations  
5.3.1 Meals and Dietary Restrictions 
1. No water (except water provided with dosing) is allowed from 1 hour prior to and until 1 hour after  dosing of study drug, but will be allowed ad libitum at all other 
times.  
2. On Day 1 , participants will fast overnight for at least 10  hours before and at least 
4 hours after dosing of study drug .  
3. On all days that participants are confined in the study site, meals and/or snacks will be provided at appropriate times. Each meal and/or snack served at the study site will be standardi sed and will be similar in caloric content and composition. 
Participants will not be required to fully consume any meal or snack.  
4. Refrain from consumption of food or drink containing poppy seeds, grapefruit or Seville oranges from  14 days before dosing of study drug until after collection of the 
final PK sample.  
5. Participants should be instructed to fast for at least 12 hours before collection of 
fasting clinical laboratory assessment samples as indicated in Section  10.2 
(Appendix 2). 
5.3.2 Caffeine, Alcohol, and Tobacco  
1. Participants will be instructed to abstain from ingesting caffeine - or xanthine -
containing products (eg, coffee, tea, cola drinks, chocolate) for 24 hours prior to 
dosing of study drug  until after collection of the final PK sample.  
Small amounts of caffeine derived from normal foodstuffs (eg, 250 mL/8 oz/1 cup  
decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz chocolate bar per da y) would not be considered a deviation to 
this restriction. 
2. Participants will be instructed to abstain from alcohol for 48 hours prior to dosing of 
study drug  until after collection of the final PK sample.  
3. Participant will abstain from use of nicotine- or tobacco- products from 3 months 
before dosing of study drug  and through confinement.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 33 of 78 5.3.3 Activity  
1. Participants will remain seated for the first 4 hours post -dose , except when they are 
supine or semi reclined for study procedures. During the first 4  hours post-dose, 
participants may be allowed to rise for brief periods under supervision (e g, in order 
to use the toilet fa cilities).  Participants  will then resume normal activity.  
2. Specific measures will be taken to prevent the participant  from missing a urine 
collection by strictly controlling and providing access to designated restrooms only. 
Participants  will be asked to void prior to entering the shower.  
3. Should AEs occur at any time, participants may be placed in an appropriate position  
or will be permitted to lie down on their right side.  
4. Participants will be instructed to refrain from strenuous physical activity which could cause muscle aches or injury, including contact sports at any time from the 
Screening V isit until completion of the study.  
5.4 Screen Failures  
A screen failure occurs when a participant who has consented to participate in the clinical study 
is not subsequently entered in the study . A minimal set of information is required to ensure 
transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details (eg,  reason for screen failure, 
such as not eligible, withdrew consent, AE), eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) due to a reason that is expected to resolve or has resolved, may be rescreened based on discus sion and 
agreement between the Investigator and the m edical monitor . 
5.5 Enrolled Participant  
A participant  will be considered enrolled if they are not a screen failure and received the study 
drug.  
5.6 Early Discontinuation  
A participant will be considered an early  discontinuer if the participant received study drug and 
did not complete all visits  or did not complete discharge criteria. Reasons for not completing all 
visits will be captured in the participant source documents and CRF .  
The definition of a study completer is provided in Section  4.4.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 34 of 78 6 STUDY DRUG  AND CONCOMITANT THERAPY  
Study drug is defined as any investigational drug(s), marketed product(s), placebo or medical 
device(s) intended to be administered to a study participant according to the study protocol.  
IDV184001AN  and [14C]-IDV184001AN  will be provided by Indivior   
 
6.1 Study Drug(s) Administered 
Table 2 Study Drug Administered 
The study drug
s’ labels will be developed in accordance with SOP and local regulatory 
requirements  and approved by Indivior . 

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 35 of 78 6.2 Preparation, Handling, Storage, and Accountability  
1. The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for  IDV184001AN and [14C]-IDV184001AN  received 
and any discrepancies are reported and resolved before use of the material as per 
the pharmacy manual.  
2. Only participants enrolled in the study may receive study drug and only authorised site staff may supply or administer study drug. The dispensing of study drug to the participant must be documented on the drug dispensing form. All study drug dispensation will be performed by a pharmacist or designee, checked by a study centre staff member and documented on a drug dispensation form. Refer to the pharmacy manual for further details.  
3. IDV184001AN , [
14C]-IDV184001AN  and study drug must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the labelled storage conditions with access limited to the Investigator and authorised site staff.  
4. The Investigator, institution, or the head of the medical institution (where applicable) is responsible for IDV184001AN , [
14C]-IDV184001AN  and study drug 
accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).  
5. Participant level dispensation of study drug must be documented on the appropriate participant level accountability form. All study drug dispensation will be performed by a pharmacist or designe e, checked by a study -site staff member and documented 
on a drug dispensation form.  
6. Used and unused IDV184001AN,  [
14C]-IDV184001AN  and study drug must be 
available for verification by the site monitor during on -site monitoring visits.  
7. Further guidance and information for the final disposition of unused IDV184001AN , 
[14C]-IDV184001AN  and study drugs are provided in the pharmacy manual.  
8. Upon completion of the study and/or as requested by Indivior, copies of  
IDV184001AN , [14C]-IDV184001AN  and study drug accountability records will be 
provided to Indivior or designee.  
6.2.1 Drug Administration 
Participants will receive the study drug directly from the Investigator or designee, under 
medical supervision.  
A record of the amount of study drug dispensed to and taken by each participant must be 
maintained and reconciled with study drug and compliance records. Study drug administration date and time will be recorded in the CRF (See Section 6.5).  
Treatment is as follows:  
o 200 mg (~100 µCi) [
14C]-IDV184001AN   on Day 1  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 36 of 78  The pharmacy at the study site will provide each dose in individual unit dose containers 
for each participant, as appropriate. When the individual dose for a participant is prepared from a bulk supply, the preparation of the dose will be confirmed by a sec ond 
member of the study -site staff.  
 Study drugs will be administered under fasted conditions with approximately 240 mL of water (see Section 5.3.1) as described in the pharmacy manual. 
 The exact clock time of dosing will be recorded.  
 Dosing compliance will be monitored as described in Section 6.5. 
6.2.2 Reporting Product Complaints  
The Investigator and study -site staff are responsible for prompt recognition and reporting of 
product quality complaints to Indivior   within 1 business day of 
identifying the issue .  
A product complaint is any concern pertaining to the manufacturing or quality control of IDV184001AN , [
14C]-IDV184001AN  or study drug and includes, but is not limited to : labelling 
defects, packaging defects, or material  or study drug that is thought to be ineffective, or has an 
appearance, taste, or odour that is outside of what is expected. See the pharmacy manual for further details.  
The following information should be provided:  
 study number  
 site contact/reported by  
 parti cipant number (if already assigned to a participant)  
 description of issue  
 picture, if available (photographs should be taken only if safe to do so/within site policy or practice to take photograph)  
Retain the product and packaging in quarantine for further  investigation, as required.  
6.3 Assignment to Study Intervention 
The Investigator is responsible for maintaining a master list (ie, a participant identification list) of all consented participants and will document all participants that did not meet study eligibility criteria (ie, screen failures), including reason(s) for ineligibility (ie, a participant screening and enrolment log).  
Each participant will be assigned a unique identification number upon the Screening Visit. Participants who complete the study s creening assessments and meet all the eligibility criteria 
will be assigned a unique identification number at the time of dosing, different from the screening number, and will receive the corresponding product.  
6.4 Blinding /Masking 
This is an open label, single treatment arm study. There is no randomi sation in this study.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 37 of 78 6.5 Study  Drug Compliance  
A qualified designee will be responsible for monitoring the administration of the timed oral 
doses. The date and time of each dose administered will be recorded in the source documents and recorded in the CRF. A mouth check will be performed by the qualified designee to ensure that the participants have swallowed the study drug. Once a participant has finished the dosing 
water, the qualified designee will use a flashlight  and a tongue depressor to check the 
participant’s mouth.  
Any deviation(s) from the prescribed dosage regimen will be recorded in the C RF. 
The time of dosing is defined as the time the participant has swallowed the study drug and the 
qualified designee has completed check of oral cavity.  
The exact clock time of dosing will be recorded.  
6.6 Dose Modification  
The dose and administration of the study drug to any participant may not be modified.  
6.7 Treatment Access  to Study Drug After the End of the Study  
Not appli cable.  
6.8 Treatment of Study  Drug Overdose 
For this study, any dose of study drug greater than that specified in the protocol will be considered an overdose. In the event of overdose, general supportive measures and close monitoring are recommended.  
Overdose s are medication errors that are not considered AEs unless there is an untoward 
medical occurrence resulting from the overdose.  
In the event of an overdose, the Investigator should do the following:  
1. Evaluate the participant to determine, in consultation wi th the medical monitor, if 
possible, whether study drug should be interrupted or whether the dose should be 
reduced. 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities.  
3. Obtain a plasma sample (for IDV184001) for PK analysis within 24 hours from the time 
of dosing  of study drug if requested by the medical monitor (determined on a case -by-
case basis).  
4. Document the quantity of the excess dose as well as the duration of the overdose.  
6.9 Prior and Concomitant Therapy  
Any medication (including prescription and non prescription medications, vitamins and dietary 
or herbal supplements) that the participant is receiving during the study must be recorded 
along with the following:  
• Reason for use  
• Dates of administration including start and end dates  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 38 of 78 • Dosage information including dose and frequency  
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
Participants must not have received concurrent treatment or treatment with an  investigational 
drug or device within 5 half- lives (if known) of the investigational agent or 30 days prior to 
dosing of study drug, whichever is longer.  
Participants must abstain from taking any prescribed or over -the- counter drugs or herbal 
remedies within 14 days or 5 half- lives (whichever is longer) prior to dosing of study drug  until 
study discharge . Thyroid hormone replacement therapy, if the particip ant has been on the 
same stable dose for at least 3 months prior to dosing, will be allowed.  After dosing of study 
drug, acetaminophen, at doses of up to 2  g/24 hours, is permitted for use at the discretion of 
the Investigator or designee. Milk of Magnesia  (ie, magnesium hydroxide) (≤60 mL per day) or 
prune juice may be administered from 24  hours after dosing at the discretion of the 
Investigator  or designee.  
Moderate or strong inhibitors/inducers of CYP3A4 or CYP2C19, including St. John’s Wort, will be prohibited within 30 days prior to dosing  of study drug until study discharge . Appropriate 
sources (eg, Flockhart Table™) will be consulted to confirm lack of PK/pharmacodynamic interaction with the study drug.  
  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 39 of 78 7 DISCONTINUATION/WITHDRAWAL  AND STOPPING CRITERIA  
7.1 Discontinuation from Study  and Study Stopping Criteria  
In rare instances, it may be necessary for a participant to permanently withdraw from study . 
See the SoE (Section 1.3) for data to be collected at the time of discontinuation of study and for 
any further evaluations that need to be completed. 
7.2 Participant Discontinuation/Withdrawal From the Study  
• A participant may withdraw from the study at any time at the participant’s own request 
for any reason (with or without providing any reason).  
• A participant may be withdrawn at any time at the discretion of the I nvestigator for 
safety, behavioural or compliance reasons.  
• At the time of discontinuing from the study, if possible, discharge  assessments should 
be conducted, as shown in the SoE  (Section  1.3).  
• Participants who terminate the study early will be asked to return to the study site 
7±2 days after dosing for follow -up procedures, and to determine if any AE has occurred 
since the last study visit, as shown in the  SoE (Section  1.3). 
• The participant will be permanently discontinued both from the study drug and from 
the study at that time.  
• The participant will be encourage d to stay up to 24 ho urs post -dose to complete 
discharge assessments.  
• If the participant withdraws consent for disclosure of future information, Indivior  may 
retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws from the study, the participant may request destruction of any samples taken and not tested, and the I nvestigator must document this in the site 
study records.  
Should any participant  withdraw or be withdrawn from the study, they will be cautioned 
against activities requiring mental alertness, judgment and physical coordination such as driving, operating machinery, or power equipment for a period of 24 hours post -dose. 
7.3 Lost  to Follow -up 
An enrolled  participant who has received study drug will be considered lost to follow -up if he 
repeatedly fails to return for sche duled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as  soon 
as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 40 of 78 • Before a participant is deemed lost to follow -up, the Inv estigator or designee must 
make every effort to regain contact with the participant [ where possible, 2 contact 
attempts (eg, telephone calls and/or emails and, if necessary a certified lett er to the 
participant’s last known mailing address or local equivalent methods) ]. These contact 
attempts should be documented in the participant’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered to 
have withdrawn from the study  and the date of withdrawal is the last contact.  
  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 41 of 78 8 STUDY ASSESSMENTS AND PROCEDURES 
• Study procedures and their timing are summarised in the SoE ( Section  1.3); individual 
clinical procedures  are described in de tail below.  
• Adherence to the study design requirements, including those specified in the SoE , is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants m eet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.  
• For this study, the blood collection for PK assessments of unlabelled IDV184001 and 
M12 (plasma) , blood (whole blood and plasma), urine, and feces collection for TRA, and 
blood (plasma), urine, and feces for the metabolic profiling are the critical parameters and need to be collected as close to the exact time point as possible.  All other 
procedures should be completed as close to the prescribed/scheduled time as possible, 
but can be performed prior to or after the prescribed/scheduled time. Any non-
scheduled procedures required for urgent evaluation of safety concerns take precedence over all routine scheduled procedures.  
• Repeat or unscheduled samples may be obtained for safety reasons.  
• In the event of a significant study -continuity issue (eg, caused by a pandemic), alternate 
strategies for participant visits, assessments, medication distribution, and monitoring may be implemented by Indivior or the Investigator, as per local health authority/ethics 
requirements.  
Table 3 Blood Volume during the Study
 

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 42 of 78 8.1 Administrative  Procedures  
8.1.1 Informed Consent Procedure  
Refer to Section 10.1.3 . 
8.1.2 Inclusion and E xclusion Criteria  
Refer  to Section 5.1 and Section 5.2. 
8.1.3 Medical History/Demography 
At screening, medical history and demographic data, including name, sex, age, race, 
ethnicity, psychiatric history, and substance use will be recorded.   
8.1.4 Concomitant Medications  
Concomitant medications will be prohibited as listed in Section 6.9. All medications 
taken by  participants during the course of the study will be recorded. 
8.1.5 Check -in Criteria  
Upon passing screening and meeting inclusion and not meeting exclusion criteria, the participant will be admitted to the study site  on Day - 1. Once admitted, participants 
must meet the following criteria prior to Day 1 dosing : 
• A check -in questionnaire will be reviewed for each participant to ensure that 
participants remain eligible for the study since screening. Questions will focus on 
inclusion and exclusion criteria and on study restrictions.  
• Participants must have a negative result obtained from the urine drug screen and 
the alcohol  test. 
o Healthy participants  who have a positive result for alcohol will be asked to 
refrain from alcohol and return the next day for retest. This may only occur once.  
• Participants must have a negative rapid  test result for COVID -19. 
• Meets ECG entry criteria . 
If any of these criteria are not met, the participant will not be enrolled.  
8.2 Efficacy and/or Immunogenicity  Assessments  
Efficacy and/or immunogenicity are not evaluated in this study . 
8.3 Safety Assessments  
Planned time points for all safety assessments are provided in the SoE  (Section  1.3). Individual 
clinical procedures are described in detail below.  
Additional safety assessments may be performed at various unscheduled time points, if 
deemed necessary by the Investigator or designee.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 43 of 78 8.3.1 Physical Examinations  
• Physical examination will be conducted as outlined in the SoE ( Section  1.3).  
• Additional physical examinations may be performed at other times, if deemed necessary 
by the Investigator  or designee.  
• A complete physical examination will include, at a minimum, an examination of all major 
body/organ systems (including skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, 
heart, abdomen, lymph nodes, and extremities). Height and weight (with participants wearing indoor, daytime clothing with no shoes) will also be meas ured and recorded as 
outlined in the SoE ( Section  1.3).  
8.3.2 Vital Signs  
• Single vital signs will include the collection of oral body temperature, respiratory rate, blood pressure, and pulse rate and will be conducted as outlined in the SoE 
(Section  1.3).  
• Blood pressure and pulse rate measuremen ts will be assessed with a completely 
automated device. Manual techniques will be used only if an automated device is not 
available.  
• Blood pressure and pulse rate will be assessed with the participant resting in a seated position for at least 5 minutes, ex cept when participants are supine or semi -reclined 
because of study procedures and/or AEs (eg, nausea, dizziness) or if deemed necessary 
by the I nvestigator or designee.  
• When scheduled pre -dose, vital signs will be measured within 2 hours prior to dosing f or 
the pre -dose time points. When scheduled post- dose, vital signs will be performed 
within approximately 15 minutes of the scheduled time point.  
8.3.3 Electrocardiograms  
• Single 12 -lead ECG will be conducted as outlined in the SoE ( Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals.  
• ECGs will be performed with participants resting  in a supine position for at least 
5 minutes. All ECG tracings will be reviewed by the Investigator or designee.  
• When scheduled pre -dose, ECGs will be measured within 2 hours prior to dosing. When 
scheduled post- dose, ECGs will be performed within approxim ately 20  minutes of the 
scheduled time point.  
8.3.4 Clinical Safety Laboratory Tests 
• See Section  10.2 (Appendix 2 ) for the list of clinical laboratory tests  to be performed and 
to the SoE ( Section  1.3) for the timing and frequency.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 44 of 78 • The Investigator must review the laboratory results, document this review and record 
any clinically relevant changes occurring during the study as an AE. The laboratory 
results must be retained with the source documents.  
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or 
baseline or are no longer considered clinically significant by the I nvestigator or medical 
monitor.  
o If such values do not return to normal/baseline within a period of time judged 
reasonable by the Investigator, the etiology  should be identified and Indivior  
notified. 
o All protocol- required laboratory tests, as defined in Section  10.2 (Appendix 2 ), must 
be conducted in accordance with the laboratory manual and the So E (Section 1.3). 
o If laboratory values from non -protocol -specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are considered clinically significant by the I nvestigator (eg, SAE or AE or dose 
modific ation), then the results must be recorded.  
o Serum chemistry tests will be performed after at least an 12- hour fast; however, in 
case of dropouts or rechecks, participants may not have fasted for 12 hours prior to 
when the serum chemistry sample is taken.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 45 of 78 8.4 Adverse Events, Serious Adverse Events, and Other Safety Reporting  
The definitions of AE s and SAEs are provided below, as are criteria for assessment of AE/SAE 
intensity and causality.  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up A Es that are serio us, considered related to the study drug or study procedures or that 
caused the participant to withdraw from the study  (see Section  7). 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study drug, whether or not considered related to the study drug.  
• NOTE: An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study drug.  
Events Meeting the AE Definition  
• Any abnormal laboratory test results (h aematology, clinical chemistry, coagulation, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from s creening (signing of the ICF), 
considered clinically significant in the medical and scientific judgement of the 
Investigat or (ie, not related to progression of underlying disease, or more severe than 
expected for the participant’s condition).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study drug administration even though it 
may have been present before signing the ICF . 
• Signs, symptoms, or the clinical sequelae of a suspected drug- drug interaction or that 
resulted in additional intervention (eg, concomitant medication, surgery).  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless 
it is an intentional overdose taken with possible suicidal/self -harming intent. Such 
overdoses should be reported regardless of sequelae.  
Events not meeting the AE definition 
• Any abnormal laboratory findings or other abnormal safety findings that are not 
considered to be clinically significant b y the Investigator. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads 
to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital, hospi talisation for elective surgery, hospitalisation 
for observation in the absence of an AE).  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 46 of 78 Definition of SAE  
An SAE is defined as any untoward medical occurrence that:  
a. Results in death 
b. Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalisation or prolongation of existing hospitalisation  
• In general, hospitalisation signifies that the participant r equires inpatient 
HOSPITALIS ATION or prolongation of existing hospitali sation  and/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalisation are AE s. If a complication prolongs 
hospitalisation or fulfils any other serious criteria, the event is serious. When in doubt as to whether “hospitalisation” occurred or was necessary, the AE should be considered serious.  
• Hospitalisation for elective treatment of a pre -existing condition that did not worsen 
from screening (signing of the ICF) is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect 
f. Other situations:  
• Medical or scientific judgement should be exercised in deciding whethe r SAE reporting 
is appropriate in other situations such as important medical events that may not be immediately life -threatening or result in death or hospitalisation but may jeopardise the 
participant or may require medical or surgical intervention to pre vent one of the other 
outcomes listed in the above definition. These events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalisation, or development of study drug dependency or study drug abuse.  
 An SAE must be reported for participants with ALT or AST ≥3  × ULN and bilirubin 
≥2 × ULN (>35% direct).  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 47 of 78 Definition of SUSAR  
A SUSAR is an SAE with at least a reasonable possibility of being related to the study drug 
(ie, the relationship cannot be ruled out), the nature or severity of which is not consistent 
with the applicable product information (eg, IB  for an unapproved investigational product 
or package insert/summary of product characteristics for an approved product).  
Assessment of Intensity  
The Investigator will assess intensity for each AE and SAE reported during the study and assign 
it to 1 of the following categories:  
• Mild: A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does  not generally interfere with usual activities of 
daily living.  
• Moderate: A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no  significant or permanent risk of harm to the research participant.  
• Severe: A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.  
Assessment of Toxicitiy  
Separately, the toxicity of AE s will be graded in accordance with the FDA Guidance for Industry: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials ( Section 10.5) . Any event not falling under one of the specific categories 
listed will be graded as a “Systemic Illness”.  
For events that occur after signing of the ICF , the maximum intensity, toxicity, and seriousness 
should be reflected in the event record.  
Assessment of Causality 
• The Investigator is obligated to assess the relationship between study drug and each 
occurrence of each AE/SAE. The relationship of each AE to study drug will be assessed using the following categories:  
o Related : An AE that follows a reasonable temporal sequence from administration of 
a drug (including the course after withdrawal of the drug), or for which a causal 
relationship is at least a reasonable possibility, ie, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, may also be responsible. 
o Not Related : An AE that does not follow a reasonable temporal sequence from 
admin istration of a drug and/or that can reasonably be explained by other factors, 
such as underlying diseases, complications, concomitant medications and concurrent treatments.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 48 of 78 • The Investigator will use clinical judg ement  to determine the relationship.   
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study drug administration will be considered and investigated.  
• For causality assessment, the I nvestigator will also consult the IB and/or product 
information, for marketed products.  
• The Investigator must review and provide an assessment of causality for each AE/SAE 
and document this in the medical notes. There may be situations in which an SAE has occurred and the I nvestigator has minimal information to include in the initial report to 
Indivior . However, it is very important that the I nvestigator always make an assessment 
of causality for every event before the initial transmission of the SAE data to Indivior . 
• The Investigator may change opinion of causality in light of follow -up information and 
send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Clinical Laboratory Changes 
Changes in laboratory values, vital signs, or other safety parameters (eg, neurological and clinical symptom assessments) as noted in the protocol are a subset of A Es and are reportable 
only if the laboratory test result is associated with accompanying symptoms, and/or requires 
additional diagnostic testing or intervention (medical, surgical), and/or requires additional 
significant treatment, and/or requires temporal or permanent discontinuation of study drug or a change to dosing other than as permitted by protocol, or if considered to be clinically 
significant by I nvestigator or medically qualified designee.  
Screening laboratory assessments, if determined to be clinically significant by the I nvestigator, 
are not A es. 
8.4.1 Time Period and Frequency for Collecting AE and SAE  Information 
All AEs and SAEs will be collected from ICF signature  until discharge  on Day 8 ( up to Day 22 ). 
Any ongoing A Es at the time of discharge will be appropriately followed -up until resolution or 
14 days (±2 days) after discharge  or early termination . Any ongoing SAEs will be followed -up 
until resolution or lost to follow -up. 
All SAEs will be recorded and reported to Indivior  or designee immediately and under no 
circumstance should this exceed 24 hours from first becoming aware of the event, as indicated in Section  8.4.3 . The Investigator will submit any updated SAE data to Indivior  within 24  hours 
of it being available.  
Investigators are not obligated to actively seek A Es or SAEs after conclusion of the study 
participation. However, if the I nvestigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and the I nvestigator considers the event to 
be reasonably related to the study drug or study participation, the I nvestigator must promptly 
notify Indivior . 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 49 of 78 8.4.2 Method of Detecting A Es and SAEs  
Care will be taken not to introduce bias when detecting A Es and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to i nquire about AE 
occurrences.  
8.4.3 Reporting and Follow -up of A Es and SAEs  
After the initial AE/SAE report, the I nvestigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabili sation, 
the event is otherwise explained or the participant is lost to follow up (as defined in 
Section  7.3). Further information on follow  up procedures is provided in Section  8.4.3.2 . 
Once the I nvestigator determines that an event meets the protocol definition of an SAE, the 
SAE will be reported to Indivior (or designated representative) by the I nvestigator (or designee) 
within 24 hours from first being aware of the event using the form provided by Indivior or 
designated representative. Any follow up information on a previously reported SAE will also be 
reported to Indivior within 24 hours.  
Where additional information is needed or expected, the I nvestigator will not wait to receive all 
informatio n before reporting the event to Indivior. The Investigator must provide an 
assessment of causality at the time of the initial report as described in Section  8.4.  
8.4.3.1  Reporting of SAEs  
SAE Reporting to Indivior via Paper SAE Reporting Form 
• The primary mechanism for reporting an SAE to Indivior Pharmacovigilance will be by 
completing the Paper  SAE Reporting Form provided by Indivior. Follow -up information 
will also be reported using the paper SAE Reporting Form.  
o The SAE Reporting Form should be completed and submitted to Indivior Pharmacovigilance:  
 
 
• The site will report all SAEs within 24 hours from first being aware  of the event. Any 
follow -up information on a previously reported SAE will also be reported to Indivior 
within 24 hours.  
8.4.3.2  Recording and Follow -up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the I nvestigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant AE/SAE information in the CRF.   
• It is not acceptable for the I nvestigator to send photo copies of the participant’s medical 
records to Indivior  in lieu of completion of the required form.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 50 of 78 • There may be instances when copies of medical records for certain cases are requested 
by Indivior Pharmacovigilance. In this case, all participant identifie rs, with the exception 
of the participant number, will be redacted on the copies of the medical records before submission to Indivior Pharmacovigilance . 
• The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
Follow -up of A Es and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/o r evaluations as medically indicated or as requested by Indivior 
Pharmacovigilance to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological 
examination s, or consultation with other health care professionals.  
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator will submit any updated SAE data to Indivior  within 24 hours of receipt 
of the information.  
• After the initial AE/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilisation , the event is otherwise explained, or the participant is lost to follow -up (as 
defined in Section 7.3).  
8.4.4 Regulatory Reporting Requirements for SAEs  
• Prompt notification by the I nvestigator to Indivior  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study drug under clinical investigation are met.  
• Indivior  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. Indivior  
will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and I nvestigators.  
• An Investigator who receives an I nvestigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from Indivior  will review and 
then file it along with the I B and/or package insert and will notify the IRB/IEC, if 
appropriate according to local requirements.  
• Investigator safety reports must be prepared for SUSAR according to local regulatory 
requirements and Indivior  policy and forwarded to I nvestigators as necessary.  
8.4.5 Pregnancy  
• Details of all pregnancies in female partners of male participants will be collected after 
study drug administration and until  90 days following dosing.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 51 of 78 • If a pregnancy is reported, the I nvestigator will record pregnancy information on  the 
appropriate form and submit it to Indivior  within 24 hours of learning of the female 
partners of male participants (after obtaining the necessary signed informed consent 
from the female partner) pregnancy .  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• All pregnancy exposure cases (unless permission has been denied), where the embryo or foetus may have been exposed to study drug ( ie,  through transmission of a medicinal 
product via semen following paternal exposure) whether associated with an AE or not, will be followed in order to collect information on the outcome of the pregnancy (ie, termination [voluntary or spontaneous] or birth). Make 2  attempts to obtain 
information after the expected due date, with 1 month between the 2 attempts. If there is no response, the case will be closed.  
• Abnormal pregnancy outcomes (eg, foetal death, stillbirth, congenital anomalies, ecto pic pregnancy, abortion [except pregnancy in habitual aborter, prophylaxis of 
abortion], pre -eclampsia, eclampsia) are considered SAEs and will be reported as such.  
• The female partners of male participants will be followed to determine the outcome of the pregnancy. The I nvestigator will collect follow -up information on the female 
partners of male participants and the neonate and the information will be forwarded to Indivior . 
• Any poststudy pregnancy -related SAE considered reasonably related to the study drug 
by the I nvestigator will be reported to Indivior  as described in Section  8.4.4 . While the 
Investigator is not obligated to actively seek this information in female partners of 
former male participants , he or she may learn of an SAE through spontaneous reporting.  
8.5 Pharmacokinetics  
• Blood samples will be collected for measurement of plasma concentrations of unlabelled IDV18400 1 and M12 , TRA measurement in plasma and whole blood, and 
plasma metabolic profiling as specified in Section 10.4 (Appendix 4 ). 
• The allowable deviation window for PK blood sample collection is detailed Section 10.4 
(Appendix 4 ).  
• Instructions for the collection and handling of biological samples will be provided in the  
Laboratory Manual. The actual date and time (24 -hour clock time) of each sample will 
be recorded.  
• Pre-dose samples should be handled, processed, analy sed, and stored separately away 
from the post- dose samples to avoid cross  contamination . 
• For urine collection, each participant will be instructed as to urine collection methods prior to collection of the pre -dose sample. All urine during an interval is to be collected. 
On Day  1, a spot collection will be obtained prior to dosing for the pre- dose sample. 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 52 of 78 Participants will be asked again to empty their bladder within approximately 15  minutes 
prior to dosing, and no urine will be collected at this time unless it is needed for the 
pre-dose sample. Only one pre -dose urine sample will be collected on Day  1. P articipants 
will be encouraged to void at the end of each collection interval. If they do void at any time during the collection interval, the time should be documented. Should this be the 
case, participants need to void again at the end of the collection period, as scheduled. However, should participants be unable to void, this will be documented as well.   
• Urine will be refrigerated during the collection intervals. At the e nd of each interval, 
urine will be pooled  and thoroughly mixed. Total urine volume will be weighed and 
recorded.  
• For feces collection, the p re-dose fecal sample will  be obtained within 48  hours prior to 
dosing. Participants will be asked to bring a fecal s ample at check -in (if produced within 
48 hours prior to dosing). Feces produced between check- in and dosing  will also be 
collected as a pre -dose sample with the sample produced nearest to dosing to be 
retained as the only pre -dose sample.  
• All fecal samples  will be collected and stored individually for analysis of  PK assessments. 
Multiple fecal samples from a given participant in a given interval will be pooled into a 
single sample at the time of homogenization. 
• Collection containers (pre -weighed) for emesis  will be available for participants 
participating in the study at all times following dosing. P articipants will be instructed at 
the beginning of the study that they should use one of the designated containers if emesis occurs at any time throughout the study following dosing. If emesis is collected in the designated container, it will be weighed and recorded, label led with participant 
identification, time, and date, and analy sed for TRA . 
• Samples from all participants will be assayed even if the participants do not complete the study. Samples will be analy sed using validated bioanalytical methods.  
• No additional analysis is planned to be performed on the PK samples for possible future research. Any additional research on these samples unspecified by this protocol will require approval from the  participants.  
8.6 Pharmacodynamics  
Pharmacodynamics are not evaluated in this study.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers 
Biomarkers are not evaluated in this study.  
8.9 Medical Resource Utilisation and Health Economics  
Medical resource utilisation and health economics  parameters are not evaluated in this study.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 53 of 78 9 STATISTICAL CONSIDERATIONS 
9.1 Statistical Hypotheses  
There are no formal statistical hypotheses for this study.  
9.1.1 Multiplicity Adjustment  
There are no inferential statistics for this study; therefore, multiplicity adjustment is not 
applicable.   
9.2 Analyses Sets  
For purposes of analysis, the following populations are defined:  
Table 4 Populations for Analysis  
Population  Description  
Screened  All participants who sign the ICF.  
PK Analysis Set  All participants who receive the study drug and have an adequate 
number of PK samples collected to derive any ADME parameter, and 
have no protocol deviations that would significantly alter 
concentrations of study drug. All available data will be included in the 
concentration and ADME parameter tables to the extent possible.  
Safety Analysis Set  All participants who r eceive the study drug.  
9.3 Statistical  Analyses  
9.3.1 General Considerations  
The SAP will be finalis ed prior to database lock and it will include a more technical and detailed 
description of the statistical analyses described in this section.  This section is a summary of the 
planned statistical analyses of the most important endpoints including primary and secondary endpoints. 
9.3.2 Primary Endpoints Analysis  
Primary endpoints analysis will be base d on a sample collection timeframe from pre -dose to 
168 hours post -dose  or longer as applicable.  Primary endpoints will be summarised for the PK 
Analysis Set.  
9.3.2.1  Mass Balance  
Total radioactivity recovery and the percent of the radioactive dose excreted in the urine and 
feces from pre -dose to at least 168 hours, as applicable, will be assessed on a per participant 
basis. Mass balance will be calculated as a sum of the percent of the TRA recovered in urine and 
feces relative to the administered radioactive dose. If emesis occurs, the calculation of mass 
balance may take into acco unt any radioactivity recovered in the vomitus as appropriate.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 54 of 78 9.3.2.2  PK Analysis  
Values will be calculated for TRA concentration equivalents, unlabell ed IDV184001 and M12 
concentration equivalents from pre -dose to at least 168 hours, as applicable, and for PK 
parameters ( listed below) using appropriate summary statistics to be fully described in the SAP.   
 TRA PK parameters in plasma and whole blood: AUC last, AUC 0-∞, AUC extrap(%) , Cmax, Tmax, λz 
and T 1/2. 
 TRA PK parameters in urine and feces: Ae t1-t2, CumAe, %Dose, Cum%Dose, and CL r (urine 
only).  
 Unlabelled IDV184001 and M12  PK parameters in plasma: AUC last, AUC 0-∞, AUC extrap(%) , 
Cmax, Tmax, λz, T1/2. 
 Ratio of unlabelled IDV184001 and M12  in plasma to plasma TRA for AUC last and C max, 
where appropriate.  
9.3.2.3  Metabolite Identification, Profiling and Quantitation 
IDV184001 metabolite identification, profiling and quantitation will be performed on plasma, 
urine, and fecal samples from pre -dose to at least 168 hours, as applicable, containing sufficient 
amounts of radioactivity. The percent of dose in urine and feces and % of AUC in plasma 
represented by each of the metabolites, if any, will be calculated using the radioactive concentration equivalent data combined with the metabolite identification, profiling and 
quantitation data. The percentage of each identified metabolite, if any, to TRA in the plasma, 
urine, and feces will be estimated based on plasma, urine, and feces metabolite identification, profiling and quantitation data. 
9.3.2.4  Whole Blood to Plasma Partitioning Ratio  
The ratio of TRA concentration equivalents in whole blood relative to plasma at each time 
matched determination of TRA in whole blood and plasma from pre -dose to at least 168 hours, 
as applicable,  will be calculated . 
9.3.3 Secondary  Endpoints  Analysis  
TEAEs will be defined as AEs that start at  or after dosing of study drug and will be summarised 
by Medical Dictionary for Regulatory Activities system organ class and preferred term. TEAEs will be summarised for the Safety Analysis Set.  
9.3.4 Tertiary Endpoints  Analysis  
9.4 Interim  Analysis  
No interim analysis is planned.  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 55 of 78 9.5 Sample Size Determination  
Approximately 7 participants will be assigned to receive study drug. According to the FDA 
Guidance for Industry: Clinical Pharmacology Considerations for Human Radiolabel led Mass 
Balance Studies ( FDA 2022), a sample size of at least 6 participants is required to meet the 
study objectives. Thus, 7 healthy male participants will be dosed to account for at most 1 
possible dropout. This sample size is limited based on clinical considerations for this type of 
study and in order to limit exposure to radioactivity . 
 
  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 56 of 78 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
10.1 Appendix  1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences international ethical guidelines  
o Applicable ICH GCP  guidelines 
o Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB , and other relev ant documents (eg, 
advertisements) must be submitted to an IRB/IEC by the I nvestigator and reviewed and 
approved by the IRB/IEC before use in  the study. If required by local regulations, the 
protocol should be re -approved by the IRB/IEC annually. The IRB/IEC must be 
constituted and operate in accordance with the principles and requirements of ICH/GCP.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to elimi nate an 
immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol may require health authority approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.  
• The Investigator will be responsible for the following, as applicable:  
o Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC  
o Notify ing the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures  
o Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 fo r clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations  
10.1.2  Financial Disclosure  
Investigators and subinvestigators will provide Indivior  with sufficient, accurate financial 
infor mation (when applicable) as requested to allow Indivior  to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the course 
of the study and for 1 year after completion of the study.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 57 of 78 10.1.3  Informed Consent Process  
• The Investigator or the I nvestigator’s representative will explain the nature of the study 
to the participant and answer all questions regarding the study. 
• Potential participants must be informed that their participation is voluntary. They will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, and privacy and data protection 
requirements, where applicable, and the IRB/IEC or study centre.  
• Written informed consent must be obtained prior to any study -related.  
• The authorised person obtaining the informed consent must also sign the ICF.  
• Participants must be reconsented to the mos t current version of the ICF(s) during their 
participation in the study, if required by the IRB/IEC.  
• A copy of the ICF(s) must be provided to the participant.  
10.1.4  Data Protection 
• Participants will be assigned a unique identifier by the study site . Any particip ant 
records or datasets that are transferred to Indivior  will contain the identifier only; 
participant names or any information which would make the participant identifiable will 
not be transferred.  
• Participants must be informed that their personal study -related data will be used by 
Indivior  in accordance with local data protection law. The level of disclosure must also 
be explained to the participant who will be required to give consent for their data to be used as described in the informed consent.  
• Participants must be informed that their study records may be examined by Clinical Quality Assurance auditors or other authorised personnel appointed by Indivior , and by 
inspectors from regulatory authorities.  
• The contract between Indivior  and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and respective 
communication and cooperation of the parties.  
• Information technology systems used to collect, process, and store  study- related data 
are secured by technical and organi sational security measures designed to protect such 
data against accidental or unlawful loss, alteration, or unauthoris ed disclosure or access.  
10.1.5  Dissemination of Clinical Study Data  
This study will be r egistered on ClinicalTrials.gov, European Clinical Trials Database , or the 
country’s clinical study registry, as appropriate, and in accordance with national, regional, and local regulations. Release of applicable clinical study results will proceed in compliance with 
local regulations in accordance with the principles of Good Publication Practice.  
A clinical study report  will be prepared following completion of the study. An Investigator 
signatory may be identified for the approval of the report if require d by applicable regulatory 
requirements.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 58 of 78 10.1.6  Data Quality Assurance  
• Data will be collected directly or transcribed from original sources by the Investigator or 
designee into the databases used for CRF generation. The Investigator is responsible for 
verifying that data entries are accurate and correct by physically or electronically signing 
the CRF.  
• Guidance on completion of CRFs will be described in the CRF completion guidelines . 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and  
regulatory agency inspections , and  provide direct access to source data documents.  
• Investigator Site Audits include, but are not limited to, review of drug supply, presence of required documents, the informed consent process, comparison of CRFs with sourc e 
documents, and any other study -specific information/documentation that the auditor 
deems appropriate for review during the audit. The I nvestigator agrees to participate 
with audits conducted at a reasonable time in a reasonable manner. Full consultation with the I nvestigator will be made prior to and during such an audit, which will be 
conducted according to Indivior’s or a Contract Research Organization ’s Quality 
Assurance  SOPs.  
• In addition, this study is subject to inspections by regulatory authorities. If such a regulatory inspection occurs, the I nvestigator agrees to allow the regulatory inspector 
direct access to all relevant study documents. The Investigator  must contact Indi vior 
immediately if this occurs and must fully cooperate with the inspection conducted at a reasonable time in a reasonable manner.  
• Monitoring details describing strategy including definition of study critical data items and processes (eg, risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk -based monitoring), methods, 
responsibilities and requirements, including handling of non -compliance issues and 
monitoring techniques (central, remote, or on-site monitoring) are provided in the 
monitoring plan . 
• Indivior  or designee is responsible for the data management of this study including 
quality checking of the data.  
• Indivior  assumes accountability for actions delegated to other individuals (eg, cont ract 
research organisations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the I nvestigator as dictated by ICH/GCP guidelines, as well as in 
accordance with the site’s Standard Operating Procedur e requirements and local 
regulations or institutional policies. No records may be destroyed without the written 
approval of Indivior . No records may be transferred to another location or party without 
written notification to Indivior . 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 59 of 78 10.1.7  Source Documents  
• Sour ce documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
Investigator’s site.  
• The Investigator is responsible for the quality of the data recorded in the CRFs . The data 
recorded should be a complete and accurate account of the participant’s record collected during the study.  
• Data reported on the CRF or entered in the e lectronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be explained. The I nvestigator may need to request previous medical records or 
transfer records, depending on the study. Also, current medical records must be available.  
• Source documents may be electronic, hard copy, or a combination of both and are 
defined as the results of original observations and activities of a clinical investigation. When using a direct entry CRF, the CRF will be considered the source document for applicable CRF elements collected directly onto a CRF . Source documents will include, 
but are not limited to, progress notes, electronic data, screening logs, and recorded data from automated instruments. Source documents will include, but are not limited to, progress notes, electronic data, screening logs, and recorded data from automated 
instruments. All source documents pertaining to this study will be maintained by the 
Investigator and made available for direct inspection by the authorised study personnel 
outlined in the ICF.  
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered  in the CRF.  
• Indivior  or designee will perform monitoring to confirm that data entered into the CRF 
by authorised site personnel are accurate, complete, and verifiable from source  
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.8  Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of participants. 
The first act of recruitment is the time study is published to the call centre  and 
Helpresearch.com website and will be the study start date.  
Study/Site Termination 
Indivior  or designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of Indivior . Study sites will be  closed upon study 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 60 of 78 completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by Indivior  or Investigator may include but are not 
limited to the following:  
For study termination:  
• Discontinuatio n of further study drug development 
For site termination:  
• Failure of the I nvestigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, Indivior  procedures , or GCP guidelines  
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by the Investigator 
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, Indivior  shall promptly inform the 
Investigators, the IRBs/IECs, the regulatory authorities, and any contract research 
organis ation(s) used in the study of the reason for termination or suspension, as specified by 
the applicable regulatory requirements. The I nvestigator shall promptly inform the participant 
and should assure appropriate participant therapy and/or follow-up. 
10.1.9  Publication Policy  
The study data will be owned by Indivior. Publication of any and all data will be at the discretion 
of Indivior. The I nvestigator will not disseminate, present, or publish any of the study data 
without the prior written approval from Indivior to do so.  
 Indivior  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, Indivior  will generally support 
publication of multicentre studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator will be designated by mutual agreement.  
 Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.  
10.2 Appendix  2: Clinical Laboratory Tests 
• The tests detailed in Table 5 will be performed by the local laboratory . 
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 . 
• Additional tests may be performed at any time during the study as determined necessary by the Investigator or required by local regulations.   
  
I N D V- 2 0 0 0  
Cli nic al St u dy Pr ot oc ol: I N D V -2 0 0 0 -1 0 5 Fi n al  I n di vi or  
1 5  M a y 2 0 2 3  
 
C o nfi d e nti al  P a g e 6 1  of 7 8  T a bl e 5 Pr ot oc ol -r e q uir e d S af et y L a b or at or y T ests  
H a e m at ol o g y   S er u m C h e mistr y *  
 H a e m o gl o bi n  
 H a e m at ocrit  
 T ot al a n d diff er e nti al l e u k ocyt e c o u nt  
 R e d bl o o d c ell c o u nt  
 Pl at el et c o u nt  
 
C o a g ul ati o n 
 Pr ot hr o m bi n ti m e/ I N R  
 Activ at e d p arti al t hr o m b o pl asti n  
   Bl o o d Ur e a Nitr o g e n  
 Bilir u bi n (t ot al a n d dir ect)  
 AL P 
 A S T  
 AL T 
 G a m m a -gl ut a m yl  Tr a nsf er as e  
 Al b u mi n  
 S o di u m  
 P ot assi u m  
 C hl ori d e  
 Gl uc os e (f asti n g)  
 Cr e ati ni n e * *  
 T ot al pr ot ei n  
 T ot al c h ol est er ol  
 Tri gl yc eri d es  
 Cr e ati n e  p h os p h o ki n as e  
 
Uri n al ysis   A d diti o n al T ests  
 p H  
 S p ecific gr a vit y  
 Pr o t ei n * * *  
 Gl uc os e  
 K et o n es  
 Bilir u bi n  
 Bl o o d * * *  
 Nitrit e * * *  
 Ur o bili n o g e n  
 L e u k ocyt e est er as e * * *    HI V -1; HI V -2 (scr e e ni n g o nl y)  
 H Bs A g (scr e e ni n g o nl y)  
 H C V  a nti b o di es (scr e e ni n g o nl y)  
 Uri n e dr u g scr e e n  
 O pi at es  
 O pi oi ds  
 A m p h et a mi n es  
 B ar bit ur at es  
 B e nz o di az e pi n es  
 C oc ai n e  
 C a n n a bi n oi ds  
 F e nt a n yl  
 Ox yc o d o n e  
 Uri n e alc o h ol scr e e n  
 C O VI D - 1 9 r a pi d t est  (c h ec k -i n o nl y)  
 
* S er u m c h e mistr y t ests will b e p erf or m e d aft er at l e ast a n 1 2- h o ur f ast; h o w e v er, i n c as e of dr o p o uts or r ec h ec ks, 
p artici p a nts  m a y n ot h a v e f ast e d f or 1 2 h o urs pri or t o w h e n t h e s er u m c h e mistr y s a m pl e is t a k e n . 
* *  At t h e Scr e e ni n g Visit, cr e ati ni n e cl e ar a nc e will b e c alc ul at e d usi n g t h e C oc kcr oft -G a ult f or m ul a . 
* * *  If uri n al ysis is a b n or m al f or pr ot ei n, bl o o d, nitrit e a n d/ or l e u k ocyt e est er as e, a micr osc o pic ex a mi n ati o n (f or r e d bl o o d 
c ells, w hit e bl o o d c ells, b act eri a, c asts, a n d e pit h eli al c ells) will b e p erf or m e d .  
I N D V- 2 0 0 0  
Cli nic al St u dy Pr ot oc ol: I N D V -2 0 0 0 -1 0 5 Fi n al  I n di vi or  
1 5  M a y 2 0 2 3  
 
C o nfi d e nti al  P a g e 6 2  of 7 8  1 0. 3  A p p e n di x  3 : C o ntr ac e pti v e G ui d a nc e a n d C oll ecti o n of Pr e g n a nc y I nf or m ati o n  
1 0. 3. 1  C o ntr ac e pti o n G ui d a nc e  
M al e P artici p a nts  
M al e p artici p a nts wit h f e m al e p art n ers of c hil d b e ari n g p ot e nti al m ust c o m pl y wit h t h e 
f oll o wi n g c o ntr ac e pti o n r e q uir e m e nts fr o m t h e ti m e of d osi n g  of st u d y dr u g u ntil at l e ast 
9 0  d a ys aft er d osi n g of st u d y dr u g .  
• All n o n -st eril e m al e p artici p a nts m ust us e hi g hl y eff ecti v e c o ntr ac e pti o n fr o m st u d y dr u g 
a d mi nistr ati o n t hr o u g h 9 0 d a ys aft er st u d y dr u g a d mi nistr ati o n if s ex u all y acti v e wit h a 
n o n -pr e g n a nt p art n er of c hil d b e ari n g p ot e nti al. Hi g hl y eff ecti v e c o ntr ac e pti o n is 
d efi n e d as:  
o Tr u e s ex u al  a bsti n e nc e  
o C o n d o m pl us p art n er’s us e o n e of  t h e f oll o wi n g :  
 Or al, i ntr a v a gi n al,  i nj ect a bl es , i m pl a nts, or tr a ns d er m al c o m bi n e d 
( estr o g e n - a n d pr o g est o g e n -c o nt ai ni n g) h or m o n al c o ntr ac e pti o n 
ass oci at e d wit h i n hi biti o n of ov ul ati o n  
 I ntr a ut eri n e d e vic e  
 I ntr a ut eri n e h or m o n e -r el e asi n g s yst e m  
 Bil at er al t u b al occl usi o n  
• N o r estricti o ns ar e r e q uir e d f or a v as ect o mi se d m al e pr ovi d e d his v as ect o m y h as b e e n 
p erf or m e d 4 m o nt hs or m or e pri or t o d osi n g. A m al e w h o h as b e e n v as ect o mi se d l ess 
t h a n 4 m o nt hs pri or t o d osi n g m ust f oll o w t h e s a m e r estricti o ns as a n o n -v as ect o mi s e d 
m al e.  
• M al e p artici p a nt m ust a gr e e n ot t o d o n at e s p er m fr o m d osi n g u ntil at l e ast 9 0  d a ys 
p ost -d os e .  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 63 of 78 10.4 Appendix  4: Pharmacokinetic Sampling Schedule 
Table 6 Blood PK sampling schedule  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 64 of 78 Table 7 Urine  sa mpling schedule  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 65 of 78 Table 8 Fecal  sam pling schedule  

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 66 of 78  
Table 9 L
ist of Whole Blood and Plasma Pharmacokinetic Parameters (non -exhaustive) 
TRA, Unlabelled IDV184001 and M12  
Cmax Maximum observed concentration  
Tmax Time of maximum observed concentration  
AUC last Area under the concentration- time curve from time 0 to the time of the last 
quantifiable concentration; calculated using the linear trapezoidal rule  
AUC 0-∞ Area under the concentration- time curve from time 0 extrapolated to infinite 
time  
AUC extrap(%)  Percent of the area under the concentration- time curve due to extrapolation 
λz Terminal phase rate constant  
T1/2 Apparent terminal half -life 
CL/F  Apparent total clearance after oral (extravascular) administration,  calculated 
as Dose/ AUC 0-∞ (parent only)  
Vz/F  Apparent volume of distribution during the terminal elimination phase after 
oral (extravascular) administration, calculated as Dose/( AUC 0-∞xλz) (parent 
only)  
MRAUC 0-∞ Metabolic ratio of the metabolite AUC 0-∞ to the parent AUC 0-∞ 
MRC max Metabolic ratio of the metabolite C max to the parent C max 

INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 67 of 78 R AUC last (plasma)  Ratio of unlabel led plasma study drug AUC last to plasma TRA AUC last 
R C max  (plasma)  Ratio of unlabel led plasma study drug C max to plasma TRA C max 
Analysis may include calculation of other PK parameters as applicable. PK  calculations will be 
performed using WinNonlin Phoenix version 8.3.4 or higher (Pharsight Corporation).  
No value for AUC 0-∞, λz, AUC extrap(%) , CL/F, Vz/F, and T 1/2 will be reported for cases that do not 
exhibit a terminal log -linear phase in the concentration -time profile . To the extent possible, 
AUC 0-∞ values for all participants including the percentage of extrapolation will be reported.  
Handling of concentrations below the limit of quantitation will be addressed in the SAP for 
calculations of PK parameters and for summary statistics of plasma concentrations.  
Table 10  List of Urine and Feces Pharmacokinetic Parameters (non -exhaustive) 
TRA 
Aet1-t2 Amount of total radioactivity excreted/recovered within a given collection interval  
CumAe  Cumulative amount of total radioactivity excreted/recovered  
%Dose Percent of administered dose excreted/recovered within a given collection 
interval  
Cum%Dose: Cumulative percent of dose excreted/recovered  
CLr Renal clearance. CL r = Ae t1-t2/AUC , where both Ae t1-t2 and AUC are determined 
over matched time interval (urine only)  
Analysis may include calculation of other PK parameters as applicable. PK calculations will be 
performed using SAS version 9.4 or higher. 
   
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 68 of 78 10.5 Appendix  5:Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled 
in Preventive  Vaccine Clinical Trials  
Guidance for 
Industry 
Toxicity Grading Scale for 
Healthy Adult and Adolescent 
Volunteers Enrolled in 
Preventive Vaccine Clinical 
Trials 
 
Additional copies of this guidance are available from the Office of Communication, 
Training and Manufacturers Assistance (HFM- 40), 1401 Rockville Pike, Suite 200 N, 
Rockville, MD 20852- 1448, or by calling 1 -800- 835- 4709 or 301- 827-1800, or from the 
Internet at http://www.fda.gov/cber/guidelines.htm. 
 
For questions on the content of this guidance, contact the Division of Vaccines and 
Related Products Applications, Office of Vaccines Research and Review at 301 -827- 3070.  
U.S. Department of Health  and Human Services  
Food and Drug 
Administration  Center for 
Biologics Evaluation and  Research  
September  2007  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 69 of 78 Guidance for Industry  
Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials  
 
I. Introduction 
Preventive vaccines are usually developed to prevent disease in a healthy population. The 
Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, regulates 
preventive vaccines under authority o f section 351 of the Public Health Service Act 
(42 U.S.C.262), as well as specific sections of the Federal Food, Drug, and Cosmetic Act, and 
reviews investigational new drug applications (INDs) and biologics license applications (BLAs). (See, for example, Title 21 CFR Parts 312, 600, and 601). Most of the clinical trials of preventive vaccines conducted to support INDs and BLAs enroll healthy volunteers in all phases of vaccine testing. The enrolment of healthy volunteers warrants a very low tolerance for risk in those 
clinical trials.  
This guidance provides you, sponsors, monitors, and investigators of vaccine trials, with 
recommendations on assessing the severity of clinical and laboratory abnormalities in healthy adult and adolescent volunteers enrolled i n clinical trials. The grading system described in the 
table can also be useful in defining a particular study’s stopping rules (eg, a certain number of adverse events, as defined in the table, may call for stopping the study). Less extreme observations (e g, mild) may not require discontinuing the study vaccine but can still contribute 
to evaluating safety by identifying parameters to focus upon in subsequent product development. Uniform criteria for categorising toxicities in healthy volunteers can improve  
comparisons of safety data among groups within the same study and also between different studies. We, FDA, recommend using toxicity grading scale tables, provided below, as a guideline for selecting the assessment criteria to be used in a clinical trial o f a preventive vaccine. We 
recommend incorporation of such appropriate, uniform, criteria into the investigational plan, case report forms, and study reports and correspondence with FDA, sponsors, monitors, 
investigators, and IRBs.  
This guidance finalizes the draft guidance of the same title dated April 2005 (70 FR 22664, May 
2, 2005).  
This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this 
topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the 
requirements of the applicable statutes and regulations. If you want to discuss an alternative 
approach, contact the appropriate FDA staff. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page  of this guidance.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 70 of 78 FDA’s guidance documents, including this guidance, do not establish legally enforceable 
responsibilities. Instead, guidances describe FDA’s current thinking on a topic and should be 
viewed only as recommendations, unless specific regulatory or statutory requirements are 
cited. The use of the word should in FDA’s  guidances means that something is suggested or 
recommended, but not required.  
II. Background 
Standardized toxicity assessment scales have been widely used to evaluate products treating 
specific diseases. For example, the National Cancer Institute’s Common Toxicity Criteria Scale and the Division of AIDS’ Toxicity Grading Scale standardize the evaluation of adverse even ts 
among patients with cancer and HIV/AIDS, respectively (Refs. 1, 2). The defined toxicity parameters in those scales are designed for patients who may already experience mild, 
moderate, or severe adverse clinical or laboratory events due to the disease process, and may 
not be appropriate for healthy volunteers.  
In the development of the toxicity grading scales for healthy volunteers, we chose parameter limit values based on published information, when such values were available (Refs. 1 -6). For 
example, t he Brighton Collaboration has developed case definitions and guidelines to evaluate 
some adverse events associated with administering vaccines (Ref. 3). In some cases, parameter limit values were based on clinical experience and experience reviewing vaccin e clinical trials 
that enroll normal healthy participants. 
Toxicity grading scales for laboratory abnormalities should consider the local laboratory 
reference values when the parameter limit values are defined. The  characterisation  of 
laboratory parameters among some populations of healthy adults and adolescents may require the exercise of clinical judgment, for example, consideration of the potential for ethnic differences in white blood cell (WBC) counts or gender differences in creatine phosphokinase (CPK) values.  
III. Toxicity grading scale  tables  
Adverse events in a clinical trial of an investigational vaccine must be recorded and monitored and, when appropriate, reported to FDA and others involved in an investigation (sponsors, IRBs , 
and investigators). (See, for example, 21 CFR 312.32, 312.33, 312.50, 312.55, 312.56, 312.60, 312.62, 312.64, 312.66). Although the use of a toxicity grading scale for adverse events would 
not replace these regulatory requirements, using a scale to  categ orise  adverse events observed 
during a clinical trial may assist you in monitoring safety and making required reports.  
Nonetheless, we believe that categorisation  or grading of data as outlined in this document is 
supplementary to and should not replace full and complete data analysis.  
These guidelines for toxicity grading scales are primarily intended for healthy adult and adolescent volunteers. The parameters in the tables below are not necessarily applicable to every clinical trial of healthy volunteers.  The parameters monitored should be appropriate for 
the specific study vaccine. For some preventive vaccines under development, it may be appropriate to include additional parameters to be monitored during a clinical trial or to alter 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 71 of 78 the choice of values in the toxicity table. For example, additional parameters might be added 
based on one or more of the following: safety signals observed in preclinical toxicology studies, the biological plausibility of the occurrence of certain adverse events, or previous experience 
with a similar licen ced product.  
As discussed above, the tables do not represent a recommendation to monitor all the listed 
parameters in all clinical trials of healthy volunteers, nor do the tables represent all possible parameters to be monito red. In addition, these tables do not represent study inclusion or 
exclusion criteria. We recommend that the parameters monitored be appropriate for the study vaccine administered to healthy volunteers participating in the clinical trial.  
A. Tables for Clinical  Abnormalities  
Local Reaction to 
Injectable Product  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially Life -
Threatening  
(Grade 4)  
Pain  Does not 
interfere with 
activity Repeated use of 
non- narcotic pain 
reliever  
>24 hours or 
interferes 
with activity  Any use of 
narcotic pain 
reliever or  
prevents daily activity  Emergency room 
(ER) visit or hospitalization 
Tenderness  Mild discomfort 
to touch  Discomfort 
with 
movement  Significant 
discomfort at 
rest ER visit or 
hospitalization 
Erythema/Redness *  2.5 – 5 cm 5.1 – 10 cm >10 cm Necrosis or  
exfoliative  
dermatitis  
Induration/Swelling **  2.5 – 5 cm and 
does not interfere  
with activity  5.1 – 10 cm 
or interferes with  
activity  >10 cm or 
prevents daily  
activity  Necrosis  
* In addition to  grading the measured local reaction at the greatest single diameter, the measurement should 
be recorded as a continuous variable. 
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement. 
 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 72 of 78 Vital Signs *  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially 
Life-
Threatening  
(Grade 4)  
Fever (°C)  ** 
(°F) ** 38.0 – 38.4  
100.4 – 101.1  38.5 – 38.9  
101.2 – 102.0  39.0 – 40 
102.1 – 104 >40 
>104  
Tachycardia – beats 
per minute  101 – 115 116 – 130 >130  ER visit or 
hospitalization 
for 
arrhythmia  
Bradycardia - beats 
per minute***  50 – 54 45 – 49 <45 ER visit  or 
hospitalization for 
arrhythmia  
Hypertension (systolic) 
- mm Hg  141 – 150 151 – 155 >155  ER visit or 
hospitalization 
for malignant  
hypertension  
Hypertension (diastolic) 
- mm Hg  91 – 95 96 – 100 >100  ER visit or 
hospitalization for malignant  
hypertension  
Hypotension (systolic) 
– mm Hg  85 – 89 80 – 84 <80 ER visit or  
hospitalization 
for hypotensive 
shock  
Respiratory Rate – 
breaths  
per minute  17 – 20 21 – 25 >25 Intubation  
* Participants  should be at rest for all vital sign  measurements.  
** Oral temperature; no recent hot or cold beverages or smoking.  
*** When resting heart rate is between 60 – 100 beats per minute. Use clinical judgement when  characterising  bradycardia 
among some healthy participant  populations, for example, conditioned athletes.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 73 of 78  
Systemic (General)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life  
Threatening 
(Grade 4)  
Nausea/vomiting  No interference  
with activity or 1 – 
2 episodes/24 
hours  Some 
interference with activity or >2 
episodes/24 
hours  Prevents daily 
activity, 
requires  
outpatient 
IV hydration  ER visit or 
hospitalization for hypotensive 
shock  
Diarrhea  2 – 3 loose stools  or 
<400 gms/24 hours  4 – 5 stools or  
400 – 800 gms/  
24 hours  6 or more 
watery stools or  
>800  gms/24 
hours or requires outpatient IV  
hydration  ER visit or 
hospitalization 
Headache  No interference 
with activity  Repeated use of 
non- narcotic pain  
reliever >24 hours or  
some 
interference 
with activity  Significant; any 
use of narcotic 
pain reliever or  
prevents 
daily activity  ER visit or 
hospitalization 
Fatigue  No interference 
with activity  Some 
interference with 
activity  Significant;  
prevents 
daily activity  ER visit or 
hospitalization 
Myalgia  No interference 
with activity  Some 
interference with 
activity Significant; 
prevents daily  
activity  ER visit or 
hospitalization 
 
Systemic Illness  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially Life-
Threatening  
(Grade 4)  
Illness or clinical 
adverse event (as 
defined according to 
applicable regulations)  No interference 
with activity  Some 
interference with 
activity not 
requiring medical  
intervention  Prevents daily 
activity and 
requires 
medical 
intervention  ER visit or 
hospitalization 
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 74 of 78 B. Tables for Laboratory  Abnormalities  
The laboratory values provided in the tables below serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Serum1 Mild (Grade 1)  Moderate 
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening 
(Grade 4)2 
Sodium – Hyponatremia mEq/L  132 – 134 130 – 131 125 – 129 <125  
Sodium – Hypernatremia mEq/L  144 – 145 146 – 147 148 – 150 >150  
Potassium – Hyperkalemia mEq/L  5.1 – 5.2 5.3 – 5.4 5.5 – 5.6 >5.6  
Potassium – Hypokalemia mEq/L  3.5 – 3.6 3.3 – 3.4 3.1 – 3.2 <3.1  
Glucose – Hypoglycemia mg /dL 65 – 69 55 – 64 45 – 54 <45 
Glucose – 
Hyperglycemia 
Fasting – mg/dL  
Random – mg/dL   
100 – 110 
110 – 125  
111 – 125 
126 – 200  
>125 
>200 Insulin 
requirements 
or hyperosmolar 
coma  
Blood Urea Nitrogen  
(BUN) mg/dL  23 – 26 27 – 31 >31 Requires  
dialysis  
Creatinine – mg/dL  1.5 – 1.7 1.8 – 2.0 2.1 – 2.5 >2.5 or requires 
dialysis  
Calcium – hypocalcemia mg/dL  8.0 – 8.4 7.5 – 7.9 7.0 – 7.4 <7.0  
Calcium – hypercalcemia mg/dL  10.5 – 11.0  11.1 – 11.5  11.6 – 12.0  >12.0  
Magnesium – 
hypomagnesemia  mg/dL  1.3 – 1.5 1.1 – 1.2 0.9 – 1.0 <0.9  
Phosphorous – 
hypophosphatemia  mg/dL  2.3 – 2.5 2.0 – 2.2 1.6 – 1.9 <1.6  
CPK– mg/dL  1.25 – 1.5 x  
ULN3 1.6 – 3.0 x ULN  3.1 –10 x ULN  >10 x ULN  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.1 2.5 – 2.7 <2.5  -- 
Total Protein – 
Hypoproteinemia  g/dL  5.5 – 6.0 5.0 – 5.4 <5.0  -- 
Alkaline phosphate – 
increase by  factor  1.1 – 2.0 x ULN  2.1 – 3.0 x ULN  3.1 – 10 x ULN  >10 x ULN  
Liver Function Tests –ALT, AST  
increase by factor  1.1 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10 x ULN  >10 x ULN  
Bilirubin – when accompanied  
by any increase in Liver Function 
Test increase by factor  1.1 – 1.25 x ULN  1.26 – 1.5 x ULN  1.51 – 1.75 x ULN  >1.75 x ULN  
Bilirubin – when Liver Function Test  
is normal; increase by factor  1.1 – 1.5 x ULN  1.6 – 2.0 x ULN  2.0 – 3.0 x ULN  >3.0 x ULN  
Cholesterol  201 – 210 211 – 225 >226  --- 
Pancreatic enzymes – amylase, 
lipase  1.1 – 1.5 x ULN  1.6 – 2.0 x ULN  2.1 – 5.0 x ULN  >5.0 x ULN  
1 The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Institutional normal reference ranges should be provided to demonstrate that they are appropriate. 
2 The clinical signs or symptoms associated with laboratory abnormalities might result in  characterisation  of the laboratory 
abnormalities as Potentially Life- Threatening (Grade 4). For example. a low sodium value that falls within a grade 3 
parameter (125 -129 mE/L) should be recorded as a grade 4 hyponatremia event if the participant had a new seizure 
associated with the low sodium value.  
3ULN is the upper limit of the normal range.  
I N D V- 2 0 0 0  
Cli nic al St u dy Pr ot oc ol: I N D V -2 0 0 0 -1 0 5 Fi n al  I n di vi or  
1 5  M a y 2 0 2 3  
 
C o nfi d e nti al  P a g e 7 5  of 7 8  H e m at ol o g y 1 Mil d ( Gr a d e 1)  M o d er at e 
( Gr a d e 2)  S e v er e ( Gr a d e 3)  P ot e nti all y 
Lif e- 
T hr e at e ni n g  
( Gr a d e 4 ) 
H e m o gl o bi n ( F e m al e) - g m/ dL  1 1. 0 – 1 2. 0  9. 5 – 1 0. 9  8. 0 – 9. 4  <. 0  
H e m o gl o bi n ( F e m al e)  
c h a n g e fr o m b as eli n e 
v al u e - g m/ dL  A ny d ecr e as e – 
1. 5  1. 6 – 2. 0  2. 1 – 5. 0  >. 0  
H e m o gl o bi n ( M al e) - g m/ dL  1 2. 5 – 1 3. 5  1 0. 5 – 1 2. 4  8. 5 – 1 0. 4  < 8. 5  
H e m o gl o bi n ( M al e)  
c h a n g e  fr o m b as eli n e 
v al u e  – g m/ dL  A ny d ecr e as e – 
1. 5  1. 6 – 2. 0  2. 1 – 5. 0  > 5. 0  
W B C I ncr e as e - c ell/ m m 3 1 0, 8 0 0 – 1 5, 0 0 0  1 5, 0 0 1 – 2 0, 0 0 0  2 0, 0 0 1 – 2 5, 0 0 0  > 2 5, 0 0 0  
W B C D ecr e as e - c ell/ m m 3 2, 5 0 0 – 3, 5 0 0  1, 5 0 0 – 2, 4 9 9  1, 0 0 0 – 1, 4 9 9  < 1, 0 0 0  
L y m p h oc yt es D ecr e as e - c ell/ m m 3 7 5 0 – 1, 0 0 0  5 0 0 – 7 4 9  2 5 0 – 4 9 9  < 2 5 0  
N e utr o p hils D ecr e as e - c ell/ m m 3 1, 5 0 0 – 2, 0 0 0  1, 0 0 0 – 1, 4 9 9  5 0 0 – 9 9 9  < 5 0 0  
E osi n o p hils - c ell/ m m 3 6 5 0 – 1 5 0 0  1 5 0 1 - 5 0 0 0  > 5 0 0 0  H y p er e osi n o p hilic  
Pl at el ets D ecr e as e d - c ell/ m m 3 1 2 5, 0 0 0 – 
1 4 0, 0 0 0  1 0 0, 0 0 0 – 1 2 4, 0 0 0  2 5, 0 0 0 – 9 9, 0 0 0  < 2 5, 0 0 0  
P T – i ncr e as e by f act or  
( pr ot hr o m bi n ti m e)  1. 0 – 1. 1 0 x  
UL N 2 1. 1 1 – 1. 2 0 x UL N  1. 2 1 – 1. 2 5 x UL N  > 1. 2 5 UL N  
P T T – i ncr e as e b y f act or 
( p arti al t hr o m b o pl asti n 
ti m e)  1. 0 – 1. 2 x UL N  1. 2 1 – 1. 4 x UL N  1. 4 1 – 1. 5 x UL N  > 1. 5 x UL N  
Fi bri n o g e n i ncr e as e - m g/ dL  4 0 0 – 5 0 0  5 0 1 – 6 0 0  > 6 0 0  --  
Fi bri n o g e n d ecr e as e - m g/ dL  1 5 0 – 2 0 0  1 2 5 – 1 4 9  1 0 0 – 1 2 4  < 1 0 0 or 
ass oci at e d wit h 
gr oss bl e e di n g 
or diss e mi n at e d 
i ntr a v asc ul ar 
c o a g ul ati o n ( DI C)  
1 T h e l a b or at ory v al u es pr o vi d e d i n t h e t a bl es s erv e as g ui d eli n es a n d ar e d e p e n d e nt u p o n i nstit uti o n al n or m al 
p ar a m et ers. I nstit uti o n al n or m al r ef er e nc e r a n g es s h o ul d b e pr o vi d e d t o d e m o nstr at e t h at t h e y ar e  a p pr o pri at e.  
2 “ UL N” is t h e u p p er li mit of t h e n or m al r a n g e.  
 
Uri n e 1 Mil d ( Gr a d e 1)  M o d er at e 
( Gr a d e 2)  S e v er e ( Gr a d e 3)  P ot e nti all y 
Lif e- 
T hr e at e ni n g 
( Gr a d e 4)  
Pr ot ei n  Tr ac e  1 +  2 +  H os pit aliz ati o n or  
di al ysis  
Gl uc os e  Tr ac e  1 +  2 +  H os pit aliz ati o n 
f or 
h y p er gl yc e mi a  
Bl o o d 
( micr osc o pic) – 
r e d bl o o d c ells 
p er  
hi g h p o w er fi el d (r bc / h pf)  1 - 1 0  1 1 – 5 0  > 5 0 a n d/ or 
gr oss bl o o d  H os pit aliz ati o n 
or p ac k e d r e d 
bl o o d c ells 
( P R B C)  
tr a nsf usi o n  
1 T h e l a b or at ory v al u es pr o vi d e d i n t h e t a bl es s erv e as g ui d eli n es a n d ar e d e p e n d e nt u p o n i nstit uti o n al n or m al 
p ar a m et ers. I nstit uti o n al n or m al r ef er e nc e r a n g es s h o ul d b e pr o vi d e d t o d e m o nstr at e t h at t h e y ar e  a p pr o pri at e.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 76 of 78 IV. References  
1. National Cancer Institute Common Toxicity Criteria, April 30, 1999. 
(http://ctep.cancer.gov/reporting/CTC- 3.html)  
2. Division of AIDS Table for Grading Severity of Adult Adverse Experienc es; August 1992. 
(http://rcc.tech -res-intl.com/tox_tables.htm) 
3. The Brighton Collaboration. Finalized Case Definitions and Guidelines. (http://brightoncollaboration.org/internet/en/index/definition___guidelines.html) 
4. HIV Vaccine Trials Network Table for Grading Severity of Adverse Experiences; September 
18, 2002. (http://rcc.tech -res-intl.com/tox_tables.htm) 
5. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, 
December 2004. (http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf) 
6. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Laboratory Reference Values. New England Journal of Medicine. 2004;351:1548- 1563.  
 
  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 77 of 78 10.6 REFERENCES 
 
Azizi H, Mirnajafi- Zadeh J, Rohampour K, Semnanian S. Antagonism of orexin type 1 receptors in 
the locus coeruleus attenuates signs of naloxone -precipitated morphine withdrawal in rats.  
Neurosci Lett. 2010;482:255- 9. 
 Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The discovery of suvorexant, the first 
orexin receptor drug for insomnia. Annu Rev Pharmacol Toxicol. 2017;57:509- 33.  
 
Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non -Opioid Neurotransmitter Systems 
that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human 
Evidence. J Pharmacol Exp Ther. 2019;371:422- 52. 
 
Flockhart DA, Thacker, D., McDonald, C., Desta, Z. The Flockhart Cytochrome P450 Drug -Drug 
Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine 
(Updated 2021). Availabe from: https://drug-interactions.medicine.iu.edu/ . Accessed on: 12 
May 2023. 
 
Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for 
Industry: Clinical Pharmacology Considerations for Human Radiolabell ed Mass Balance Studies 
(May 2022). Accessible on the page https://www.fda.gov/media/158178/download. Accessed 
on: 12 May 2023. 
 
Food and Drug Administration CFR - Code of Federal Regulations Title 21, Volume 5, Revised as 
of January 17, 2023 [CITE: 21CFR361.1] accessible on the page: 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ 
CFRSearch.cfm?CFRPart=361&showFR=1.  Accessed on: 12 May 2023.  
 
Hooshmand B, Azizi H, Javan M, Semnanian S. Intra- LC microinjection of orexin type -1 receptor 
antagonist SB -334867 attenuates the expression of glutamate -induced opiate withdrawal like 
signs during the active phase in rats. Neurosci Lett. 2017;636:276 -81. 
 
ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological 
Protection. ICRP Publication 103. Ann. ICRP 37 (2- 4). Accessible at 
http://journals.sagepub.com/doi/pdf/10.1177/ANIB_37_2-4.  Accessed on: 12 May 2023. 
 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston -Jones G, Multiple roles for 
orexin/hypocretin in addiction. Prog Brain Res . 2012;198:79- 121.  
INDV- 2000  
Clinic al Study Protocol: INDV -2000 -105 Final Indivior  
15 May 2023  
 
Confidential  Page 78 of 78  
Markham, A. Daridorexant: First Approval.  Drugs 2022;82:601 –7. 
 
Murphy P , Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi 
L, Satlin A. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of 
insomnia disorder: results from a Bayesian, adaptive, randomized, doubleblind, placebo -
controlled study. J Clin Sleep Med. 2017;13:1289 -99  
 
National Council on Radiation Protection and Measurements (NCRP) Report No. 160, Ionizing 
Radiation Exposure of the Population of the United State, National Council on Radiation Protection and Measurements, March 2009.  
 
Thannickal TC, John J, Shan L; Swaab DF, Wu MF, Ramanathan L, McGregor R, Chew KT, 
Cornford M, Yamanaka A, Inutsuka A, Fronczek R, Lammers GJ, Worley PF, Siegel JM. Opiates increase the number of hypocretin- producing cells in hum an and mouse brain and reverse 
cataplexy in a mouse model of narcolepsy. Sci Transl Med. 2018;10:447.  